

1 **Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory**  
2 **viruses and SARS-CoV-2 variants**

3  
4 Welch, N.L.<sup>\*1,2</sup>, Zhu, M.<sup>†1,3</sup>, Hua, C.<sup>†1,4</sup>, Weller, J.<sup>1,5</sup>, Ezzaty Mirhashemi, M.<sup>1</sup>, Mantena,  
5 S.<sup>1</sup>, Nguyen, T.G.<sup>1</sup>, Shaw, B.M.<sup>1,4</sup>, Ackerman, C.M.<sup>1,3</sup>, Thakku, S.G.<sup>1,6</sup>, Tse, M.W.<sup>1,3</sup>,  
6 Kehe, J.<sup>1,3</sup>, Bauer, M.R.<sup>1,7</sup>, Uwera, M-M.<sup>1</sup>, Eversley, J.S.<sup>4</sup>, Bielwaski, D.A.<sup>4</sup>, McGrath,  
7 G.<sup>4</sup>, Braidt, J.<sup>4</sup>, Johnson, J.<sup>1</sup>, Cerrato, F.<sup>1</sup>, Petros, B.A.<sup>1,6,8</sup>, Gionet, G.L.<sup>1</sup>, Jalbert, S.K.<sup>9</sup>,  
8 Cleary, M.L.<sup>9</sup>, Siddle, K.J.<sup>1,10</sup>, Happi, C.T.<sup>1,11,12</sup>, Hung, D.T.<sup>1,13</sup>, Springer, M.<sup>9</sup>, MacInnis,  
9 B.L.<sup>1,14</sup>, Lemieux, J.E.<sup>1,4</sup>, Rosenberg, E.<sup>4,15</sup>, Branda, J.A.<sup>§4,15</sup>, Blainey, P.C.<sup>§1,2</sup>, Sabeti,  
10 P.C.<sup>§\*1,9,10,16,17</sup>, Myhrvold, C.<sup>§\*18</sup>.

11  
12 <sup>1</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA. <sup>2</sup>Harvard Program in  
13 Virology, Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.  
14 <sup>3</sup>Department of Biological Engineering, MIT, Cambridge, MA, USA. <sup>4</sup>Division of  
15 Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston,  
16 MA, USA. <sup>5</sup>Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.  
17 <sup>6</sup>Division of Health Sciences and Technology, Harvard Medical School and MIT,  
18 Cambridge, MA, USA. <sup>7</sup>Harvard Program in Biological and Biomedical Sciences,  
19 Harvard Medical School, Boston, MA 02115, USA. <sup>8</sup>Harvard/MIT MD-PhD Program,  
20 Harvard Medical School, Boston, MA, USA. <sup>9</sup>Department of Systems Biology, Harvard  
21 Medical School, Boston, MA 02115, USA, <sup>10</sup>Department of Organismic and Evolutionary  
22 Biology, Harvard University, Cambridge, MA, USA. <sup>11</sup>African Centre of Excellence for  
23 Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Osun State,  
24 Nigeria. <sup>12</sup>Department of Biological Sciences, College of Natural Sciences, Redeemer's  
25 University, Ede, Osun State, Nigeria. <sup>13</sup>Molecular Biology Department and Center for  
26 Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA,  
27 USA. <sup>14</sup>Department of Immunology and Infectious Disease, Harvard T.H. Chan School  
28 of Public Health, Harvard University, Boston, MA, USA. <sup>15</sup>Department of Pathology,  
29 Massachusetts General Hospital, Boston, MA, USA. <sup>16</sup>Koch Institute for Integrative  
30 Cancer Research at MIT, Cambridge, MA, USA. <sup>17</sup>Howard Hughes Medical Institute,  
31 Chevy Chase, MD, USA. <sup>18</sup>Department of Molecular Biology, Princeton University,  
32 Princeton, NJ, USA.

33  
34  
35 † These authors contributed equally.

36 § These authors supervised this work.

37 \* Address correspondence to; [nicole\\_welch@g.harvard.edu](mailto:nicole_welch@g.harvard.edu), [pardis@broadinstitute.org](mailto:pardis@broadinstitute.org)  
38 or [cmhrvol@princeton.edu](mailto:cmhrvol@princeton.edu)

39  
40  
41  
42  
43  
44  
45 **Key words:** diagnostic, SARS-CoV-2, COVID-19, CRISPR, respiratory viruses,  
46 variants, multiplexed, high-throughput, quantification

## 47 **Abstract**

48  
49 The COVID-19 pandemic has demonstrated a clear need for high-throughput,  
50 multiplexed, and sensitive assays for detecting SARS-CoV-2 and other respiratory  
51 viruses as well as their emerging variants. Here, we present microfluidic CARMEN  
52 (mCARMEN), a cost-effective virus and variant detection platform that combines  
53 CRISPR-based diagnostics and microfluidics with a streamlined workflow for clinical  
54 use. We developed the mCARMEN respiratory virus panel (RVP) and demonstrated its  
55 diagnostic-grade performance on 533 patient specimens in an academic setting and  
56 then 166 specimens in a clinical setting. We further developed a panel to distinguish 6  
57 SARS-CoV-2 variant lineages, including Delta and Omicron, and evaluated it on 106  
58 patient specimens, with near-perfect concordance to sequencing-based variant  
59 classification. Lastly, we implemented a combined Cas13 and Cas12 approach that  
60 enables quantitative measurement of viral copies in samples. mCARMEN enables high-  
61 throughput surveillance of multiple viruses and variants simultaneously.

## 62 **Introduction**

63  
64  
65 COVID-19 has exposed critical gaps in our global infectious disease diagnostic and  
66 surveillance capacity<sup>1</sup>. The pandemic rapidly necessitated high-throughput diagnostics  
67 to test large populations<sup>2</sup>, yet early diagnostic efforts met technical challenges that cost  
68 the United States precious time in its early response<sup>3,4</sup>. Other challenges developed as  
69 the pandemic progressed that point towards an additional need for highly multiplexed  
70 surveillance technologies. These challenges include the co-circulating human  
71 respiratory viruses that cause symptoms similar to COVID-19<sup>5,6</sup> and emerging SARS-  
72 CoV-2 variants of concern (VOCs) with mutations that impact viral fitness and clinical  
73 disease prognosis<sup>7,8</sup>.

74  
75 An ideal diagnostic would also have surveillance capabilities to process hundreds of  
76 patient samples simultaneously, detect multiple viruses, differentiate between viral  
77 variants, and quantify viral load<sup>9,10</sup>; yet no such test currently exists. As it stands, there  
78 is a trade-off between clinically approved high-throughput diagnostics and multiplexed  
79 methods in the number of patient samples and/or pathogens tested simultaneously<sup>11-13</sup>.  
80 As examples, reverse transcription-quantitative PCR, RT-qPCR is high-throughput by  
81 testing at least 88 samples, but for 1-3 analytes at a time<sup>3,14,15</sup>; multiplexed techniques  
82 such as, Cepheid Xpert Xpress detects 4 respiratory viruses in up to 16 samples per  
83 run<sup>16</sup>, and BioFire detects 22 respiratory pathogens in 1 sample simultaneously<sup>17</sup>.  
84 Additionally, these and other clinical diagnostic methods, except ChromaCode<sup>18,19</sup>, do  
85 not comprehensively detect SARS-CoV-2 variant mutations<sup>20,21</sup>. Instead, detecting  
86 SARS-CoV-2 variants has largely been achieved through next-generation sequencing  
87 (NGS)<sup>22,23</sup>, which is time-consuming, expensive, and requires bioinformatic expertise to  
88 interpret<sup>7,24-27</sup>.

89  
90 CRISPR-based diagnostics offer an alternative approach to detecting multiple viruses  
91 and variants<sup>28-30</sup>. CRISPR effector proteins Cas12 or Cas13 activate upon CRISPR  
92 RNA (crRNA)-target binding which unleashes their collateral cleavage activity on a

93 fluorescent reporter for readout of viral positivity status<sup>31–34</sup>. The crRNA-target binding  
94 events are highly specific and altered by the presence of sequence variation. Maximally  
95 active crRNA design has been accelerated by machine learning and other  
96 computational methods<sup>35</sup>. Nonetheless, most CRISPR diagnostics detect one or two  
97 targets per sample<sup>31,36</sup>, which is not sufficient for differential diagnosis via  
98 comprehensive microbe or variant identification.  
99

100 To scale up the capabilities of CRISPR-based diagnostics, we developed Combinatorial  
101 Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN)<sup>37</sup> which  
102 parallelizes nucleic acid detection (Fig. 1a). The first generation of CARMEN, referred to  
103 here as CARMEN v1, could detect 169 human-associated viruses in 8 samples  
104 simultaneously. In CARMEN v1, samples and Cas13-crRNA complexes remain  
105 separately confined for barcoding and emulsification prior to pairwise droplet  
106 combination for detection by fluorescence microscopy. This allows each sample to be  
107 tested against every crRNA. CARMEN v1 is a powerful proof-of-concept for multiplexed  
108 CRISPR-based detection, but it is difficult to use in a clinical setting given its use of  
109 custom-made imaging chips and readout hardware, manually intensive 8-10 hour  
110 workflow, and low-throughput sample evaluation.  
111

112 To fulfill the public health need for a clinically relevant surveillance technology that  
113 detects multiple viruses and variants quickly, we developed microfluidic CARMEN  
114 (mCARMEN). mCARMEN builds on CARMEN v1 and uses commercially available  
115 Fluidigm microfluidics and instrumentation<sup>38</sup>. mCARMEN on Fluidigm allows for a faster  
116 and less labor-intensive alternative to CARMEN v1 and requires 3x less sample input  
117 compared to single analyte RT-qPCR testing. The mCARMEN workflow can process  
118 188 patient samples for up to 23 respiratory viruses and variants in under 5 hours, and  
119 costs <\$10 USD per sample (Supp. Table 1). In an academic setting, we detected 21  
120 human respiratory viruses by mCARMEN (Supp. Table 2). Then, in a CLIA-certified  
121 laboratory at Massachusetts General Hospital (MGH), we validated the condensed  
122 respiratory virus panel (RVP), comprised of nine common viruses and a human internal  
123 control, RNase P. Further, we developed a SARS-CoV-2 variant identification panel  
124 (VIP) which we immediately applied to the detection of Omicron as cases emerged in  
125 the Boston area without any changes to the assay. Additionally, we combined Cas13  
126 detection with Cas12 to quantify viral genome copies in samples, yielding results  
127 comparable to RT-qPCR. To our knowledge, mCARMEN is the only diagnostic that  
128 combines surveillance capabilities into a single technology platform with the ability to  
129 test hundreds of samples in a day for multiple respiratory viruses and variants, while  
130 also being able to quantify viral genomic copies.  
131

## 132 **Results**

### 134 **CARMEN implementation on Fluidigm for detecting 21 human respiratory viruses**

135  
136 CARMEN v1<sup>37</sup> is limited by custom instrumentation requirements and labor-intensive  
137 protocols which is why we sought to develop a scalable technology that could be  
138 broadly implemented. Microfluidic CARMEN (mCARMEN) meets these requirements

139 and eliminates the color-coding and dropletization needs of CARMEN v1 by using  
140 commercially available integrated fluidic circuits (IFCs) on the Fluidigm Biomark<sup>38</sup>  
141 (Fluidigm, San Francisco, CA) (Fig. 1a). By leveraging Fluidigm microfluidics, we  
142 overcame the need for a custom microscope and chips as well as data analysis  
143 expertise, which were required for CARMEN v1. The Fluidigm IFCs use a specific  
144 number of assay combinations: 192 samples by 24 detection assays or 96 samples by  
145 96 detection assays which are all spatially separated. After manual IFC loading, the  
146 Fluidigm controller moves the samples and detection assays through individual  
147 channels on the IFC until they reach the chip reaction chamber, where they are  
148 thoroughly mixed. We measure fluorescence on the Fluidigm Biomark with our custom  
149 automated protocols that take images of the IFC chip every 5 minutes for 1-3 hours at  
150 37°C (Extended Data Fig. 1a).

151  
152 In our first implementation of the mCARMEN platform, we designed a panel to detect 21  
153 clinically relevant human respiratory viruses (Supp. Table 2). This includes all viruses  
154 covered by BioFire RP2.1 - SARS-CoV-2, four other human-associated coronaviruses  
155 and both influenza strains - as well as a few additional illness inducing viruses<sup>39</sup>. To  
156 generate maximally active virus-specific crRNAs and PCR primers to detect the 21  
157 viruses, we applied the assay design method ADAPT (Activity-informed Design with All-  
158 inclusive Patrolling of Targets; described in methods)<sup>35</sup>. We were able to encompass  
159 the full genomic diversity of these viral families by including multiple primers, if needed.

160  
161 We compared the performance of mCARMEN to CARMEN v1 for detecting synthetic  
162 DNA fragments recapitulating the 21 viral targets, and found mCARMEN had the same  
163 (13 viruses) or better (8 viruses) analytical sensitivity compared with CARMEN v1 (Fig.  
164 1b and 1c, Extended Data Fig. 1b). Both mCARMEN and CARMEN v1 had 100%  
165 analytical specificity, but mCARMEN was 100% sensitive to 10<sup>2</sup> copies/μL and 98.4%  
166 sensitive to 10<sup>1</sup> copies/μl while CARMEN v1 was only 86% and 77.8% sensitive,  
167 respectively. Moreover, the mCARMEN reaction rate is accelerated compared with  
168 CARMEN v1, resulting in faster initial detection and signal saturation of targets (Fig. 1d,  
169 Extended Data Fig. 1c). This is likely due to the higher temperature at reaction initiation  
170 for mCARMEN (37°C) than for CARMEN v1 (25°C), and the extensive sample-detection  
171 assay mixing that occurs in the mCARMEN IFC, rather than merged droplets mixing by  
172 diffusion in CARMEN v1.

173  
174 We then benchmarked the performance of both CARMEN diagnostics against RT-  
175 qPCR<sup>40</sup> and/or unbiased metagenomic NGS on patient specimens. We obtained a set  
176 of 6 SARS-CoV-2-positive, 4 SARS-CoV-2-negative, and 8 influenza A virus (FLUAV)-  
177 positive patient specimens for initial testing. mCARMEN and CARMEN v1 had 100%  
178 concordance with RT-qPCR, NGS, and each other (Fig. 1e). We also compared  
179 performance using two different fluorescent reporters, RNase Alert (IDT, Coralville, IA)  
180 and a custom 6-Uracil-FAM (polyU) reporter<sup>34</sup>. We found enhanced sensitivity when  
181 using a polyU fluorescent reporter due to LwaCas13a's preference to cleave at  
182 uracils<sup>28,29</sup> (Extended Data Fig. 2a&b).

183

184 Aside from SARS-CoV-2 and influenza viruses, the remaining 19 viruses detectable by  
185 mCARMEN lack a recognized gold-standard clinical diagnostic. Thus, we compared  
186 mCARMEN to unbiased metagenomic NGS results for the characterization of 58 pre-  
187 pandemic unknown samples collected from patients with a presumed upper respiratory  
188 infection (Fig. 1f, Supp. Table 3, Extended Data Fig. 2c&d). Both mCARMEN and NGS  
189 detected the same respiratory viruses in 12 specimens (7 FLUAV, 2 HCoV-229E, 1  
190 HCoV-NL63, 1 HCoV-OC43, and 1 HMPV), neither detected respiratory viruses in 42  
191 specimens, and they had differing results for 4 specimens, with 93% overall  
192 concordance based on an average of ~3 million reads per specimen. Nine of the 12  
193 specimens positive by both methods assembled complete genomes while the remaining  
194 3 assembled partial or no genomes but had >10 reads (2 FLUAV, 1 HMPV). mCARMEN  
195 missed 1 virus-positive specimen detected by NGS, a partial FLUAV genome. We found  
196 no sequencing reads spanning the mCARMEN amplicon, suggesting degradation was  
197 responsible for the result. mCARMEN detected virus in 3 specimens (1 FLUAV, 2 HRV)  
198 where NGS did not detect any viral reads. While we cannot rule out false positive  
199 results, metagenomic sequencing has been shown to have poor sensitivity for low viral  
200 copy samples<sup>6,24,41</sup>.

201

### 202 **Streamlining mCARMEN respiratory virus panel for future clinical use**

203

204 With a drive towards clinical applications, we aimed to optimize the mCARMEN  
205 workflow. To do so, we decreased the manual labor and processing time from >8 hours  
206 to <5 hours by implementing automated RNA extraction, using a single-step RNA-to-  
207 DNA amplification with 1 primer pool, and reducing the duration of detection readout  
208 (Fig. 2a, Extended Data Fig. 3a). We then preliminarily evaluated the optimized  
209 workflow on 21 SARS-CoV-2 positive and 8 negative patient specimens, and found  
210 greater sensitivity over the original two-step amplification method (Extended Data Fig.  
211 3b).

212

213 For an end-to-end mCARMEN workflow, we developed software to be used alongside  
214 clinical testing to provide patient diagnoses (Extended Data Fig. 6). The software uses  
215 the final image at 1 hour post-reaction initiation as input, then automatically validates  
216 controls to make 1 of 3 calls: “detected,” “not detected,” or “invalid” for each combination  
217 of sample and crRNA.

218

219 Lastly, we wanted to condense mCARMEN for focused clinical use and did so by  
220 developing a respiratory virus panel (RVP) to detect 9 of the most clinically-relevant  
221 viruses (SARS-CoV-2, HCoV-HKU1, HCoV-OC43, HCoV-NL63, FLUAV, FLUBV, HPIV-  
222 3, HRSV, and HMPV) and a human internal control, (RNase P). These nine viruses  
223 were included on RVP based on if they heavily circulate in the population and have  
224 capacity to cause respiratory virus symptoms, while others were excluded if genomic  
225 diversity was difficult to account for concisely, such as HRV<sup>42</sup>. We first conducted range-  
226 determining limit of detection (LOD) studies for the 9 viruses on mCARMEN RVP in a  
227 research laboratory. The preliminary LOD was within the range of 100-1,000 copies/mL  
228 for SARS-CoV-2, FLUAV, FLUBV, HCoV-HKU1, HCoV-NL63, HCoV-OC42, and 1,000-  
229 20,000 copies/mL for HPIV-3, HMPV, HRSV (Extended Data Figure 5a, Supp. Table 4),

230 with robust performance from the SARS-CoV-2 crRNA as well as all RVP crRNAs in  
231 combination (median AUCs of 1 and 0.989, respectively) (Extended Data Figure 5b-g).

232  
233 To benchmark mCARMEN RVP performance to comparator assay results, we analyzed  
234 390 SARS-CoV-2-positive and 143 negative patient specimens, and compared these  
235 results to both prior and concurrent RT-qPCR evaluation (Fig. 2c). By the time of  
236 comparative evaluation the number of RT-qPCR positive specimens dropped from 390  
237 to 317, suggesting significant sample degradation either from extended sample storage  
238 or multiple freeze-thaw cycles. Nonetheless, mCARMEN was able to identify all 317  
239 (100% sensitivity) of the concurrent RT-qPCR positive specimens. We noted,  
240 mCARMEN further detected SARS-CoV-2 in 44 specimens that tested positive by prior  
241 RT-qPCR, but were missed by concurrent RT-qPCR testing, suggesting mCARMEN is  
242 more robust to sample quality issues. Indeed, if we categorize putative true positives as  
243 all specimens that tested positive by prior RT-qPCR as well as present-day RT-qPCR  
244 and/or mCARMEN, mCARMEN would have 100% sensitivity compared to 88% for RT-  
245 qPCR. mCARMEN also detected SARS-CoV-2 in 3 specimens that tested negative by  
246 both prior and concurrent RT-qPCR (Fig. 2e). While we cannot rule out the possibility of  
247 false-positives, several pieces of evidence suggest they are more likely to be true  
248 positives: mCARMEN demonstrates higher sensitivity over concurrent RT-qPCR testing,  
249 these specimens are from suspected SARS-CoV-2 cases based on clinical features,  
250 and mCARMEN did not detect SARS-CoV-2 in any clinical specimens prior to the  
251 pandemic (Fig. 1, Extended Data Fig. 2).

252  
253 We further evaluated the analytical sensitivity of RVP by correlating RVP fluorescence  
254 signals to Ct values obtained from concurrent RT-qPCR testing (TaqPath,  
255 ThermoFisher, CA). Of the 317 specimens positive for SARS-CoV-2 by mCARMEN  
256 RVP and both RT-qPCR results, 217 had Ct values <30, suggesting moderate-to-high  
257 viral genome copies. By RVP, all 217 specimens (100%) reached signal saturation by 1  
258 hour post-reaction initiation (Fig. 2c&d, Extended Data Fig. 6a&b). The remaining 100  
259 specimens had Ct values between 30-36 and all but 6 samples (94%) reached signal  
260 saturation by 1 hour. In total, 98% (311/317) of the specimens reached saturation by 1  
261 hour indicating mCARMEN can rapidly deem viral positivity status for a range of Ct  
262 values. Even 17 of the 44 (~40%) RVP positive specimens, but not concurrently RT-  
263 qPCR positive, reached saturation by one hour; the slower saturation of these  
264 specimens further suggests detection issues caused by sample degradation and/or low  
265 viral genome copy number. We also evaluated RVP fluorescence for detecting an  
266 internal control and human housekeeping gene, RNase P. We found 525 of the 533  
267 (98.5%) patient specimens reached saturation for RNase P by 1 hour (Extended Data  
268 Fig. 6c&d, described in methods).

269  
270 Additionally, we used unbiased metagenomic NGS as a metric to evaluate RVP  
271 performance. As controls for NGS, we sequenced a set of true SARS-CoV-2 negative  
272 specimens (i.e., negative by all three results, RVP and 2x RT-qPCR) (n=16), and true  
273 SARS-CoV-2 positives (n=15) with a range of Ct values (15-34) (Fig. 2e, Supp. Table  
274 3). Fifteen out of the 16 true negatives had no more than 2 reads mapped to the SARS-  
275 CoV-2 genome, in line with <10 reads expected for negative specimens, while 1

276 specimen had 11 reads by NGS (average ~8.8 million reads per specimen). All true  
277 positive specimens had >10 aligned viral reads, ranging from 16 to 802,306 reads, by  
278 NGS (100% sensitivity). Only specimens with Ct values <25 (n=8) were able to  
279 assemble complete genomes, while specimens with Ct values >25 (n=7) had <200  
280 reads map to SARS-CoV-2.

281  
282 By NGS, we then evaluated 22 RVP and RT-qPCR discordant specimens, and 8  
283 specimens for which RVP detected other respiratory viruses. The 22 discordant  
284 samples included 13 positive by RVP and prior testing but concurrently negative by RT-  
285 qPCR, 6 positive by prior testing, but negative by concurrent RVP and RT-qPCR, and 3  
286 positive by RVP but negative by both RT-qPCR results. All but 1 of the 22 (95%)  
287 discordant specimens had <10 viral reads by NGS. The single specimen with >10 reads  
288 was positive by RVP and prior RT-qPCR, but not concurrent testing, yet just 22 reads  
289 mapped to SARS-CoV-2. NGS additionally failed to detect other respiratory viruses in  
290 the 8 RVP-positive specimens. RVP identified 4 SARS-CoV-2 co-infections (2 HCoV-  
291 HKU1, 1 HPIV-3 and 1 HRSV), and 4 viruses in SARS-CoV-2-negative specimens (3  
292 FLUAV and 1 HCoV-NL63). Given these specimens also had <10 viral reads aligned by  
293 NGS, we can neither validate our results as positive nor rule out the possibility of false-  
294 negatives by NGS; these samples are likely low viral quantity implying mCARMEN and  
295 RT-qPCR are more sensitive.

296

### 297 **Evaluation of RVP performance in a clinical setting**

298

299 We implemented mCARMEN RVP in the CLIA-certified Clinical Microbiology Laboratory  
300 at Massachusetts General Hospital (MGH) to establish assay sensitivity and specificity  
301 for clinical validation following FDA guidelines<sup>43</sup>. We first evaluated the limit of detection  
302 (LOD), defined as the lowest concentration yielding positive results for at least 19 of 20  
303 replicates. After recapitulating the 9 viral targets on RVP, we found the LOD for HCoV-  
304 HKU1, HCoV-NL63, HCoV-OC43, FLUAV, and FLUBV were 500 copies/mL while  
305 HMPV and SARS-CoV-2 were 1,000 copies/mL, and HPIV-3 and HRSV were 10,000  
306 copies/mL (Fig. 3a&b, Extended Data Fig. 7a). The LOD likely varies between viral  
307 targets for a few reasons: the crRNAs have varying activity levels on their intended  
308 target and differing input materials were used based on sample availability.

309

310 After establishing the single analyte LODs, we asked whether co-infections impacted  
311 the sensitivity for each virus detected by RVP. To do so, we added SARS-CoV-2 at a  
312 constant, 2x LOD, concentration to the remaining 8 viruses on RVP at varying  
313 concentrations at or above their respective LOD (Extended Data Fig. 7b). We observed  
314 no loss in our ability to detect SARS-CoV-2. However, we noticed a decrease in signal  
315 intensity for the other viruses at lower concentrations, yet only one virus, HPIV-3, had a  
316 10-fold higher LOD.

317

318 Although we observed no cross-reactivity between RVP panel members in the research  
319 setting (Fig. 1 and 2), we followed FDA guidelines to conduct more stringent assay  
320 inclusivity and specificity analyses against common respiratory flora and other viral  
321 pathogens. *In silico* analysis revealed the primers on RVP are >92% inclusive of the

322 known genetic diversity of each viral species, with additional inclusivity coming from  
323 crRNA-target recognition, for an overall >95% inclusivity (Supp. Table 5). When  
324 examining off-target activity *in silico*, FDA defines cross-reactivity as >80% homology  
325 between one of the primers or probes to any microorganism. We found no more than  
326 75% homology between the RVP primer and crRNA sequences to other closely related  
327 human pathogens (Supp. Table 6). This implies that off-target detection will rarely, if  
328 ever, occur.

329  
330 Following *in silico* analysis, we evaluated RVP specificity experimentally. We  
331 computationally designed position-matched synthetic gene fragments from closely  
332 related viral species, including both human- and non-human-infecting species. When  
333 evaluating these gene fragments, only SARS-CoV-2 and RaTG13 showed cross-  
334 reactivity (Fig. 3c, Extended Data Fig. 8). This cross-reactivity is expected, however,  
335 because the RaTG13 amplicon evaluated shares 100% nucleotide identity with the  
336 SARS-CoV-2 amplicon in our assay. We did not observe any cross-reactivity when  
337 using viral seed stocks, genomic RNA, or synthetic RNA from ATCC or BEI (Supp.  
338 Table 7). Therefore, we found RVP to have 100% analytical specificity.

339  
340 Finally, the FDA recommends testing a minimum of 30 known-positive clinical  
341 specimens for each pathogen in an assay, as well as 30 negative specimens. Where  
342 positive specimens are not available, the FDA allows the creation of contrived samples,  
343 by spiking viral genomic material at clinically-relevant concentrations into a negative  
344 specimen. Each virus evaluated must have a minimum of 95% agreement performance,  
345 both positive percent agreement (PPA) and negative (NPA), to clinically-approved  
346 comparator assays.

347  
348 At MGH, archived clinical specimens had been evaluated at the time of collection using  
349 one of two comparator assays: Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV  
350 multiplexed assay or BioFire RP2.0 multiplexed assay (Extended Data Fig. 9, Supp.  
351 Table 3). These included 166 specimens with 137 total viral clinical results: 31 FLUAV,  
352 30 SARS-CoV-2, 30 HRSV, 29 FLUBV, 8 HMPV, 5 HCoV-NL63, 1 FLUBV and HCoV-  
353 NL63 co-infection, 1 HCoV-HKU1, 1 HCoV-OC43 and 30 clinically negative. Given these  
354 specimens can be degraded by multiple freeze thaws, we concurrently tested all  
355 specimens by BioFire RP2.0 or TaqPath COVID-19 Combo Kit for the SARS-CoV-2  
356 specimens. We also supplemented this evaluation with 30 contrived samples for each of  
357 the following viruses for which we did not have enough positive specimens: HCoV-  
358 HKU1, HCoV-OC43, HCoV-NL63, HPIV-3, and HMPV (described in methods), for a  
359 total of 150 contrived samples.

360  
361 All of the RVP viral targets individually had 100% NPA, and all, except HMPV, had  
362 >95% PPA to their respective previous comparator assay result, exceeding the  
363 minimum clinical performance set by the FDA (Fig. 3d). Of the 137 previously positive  
364 clinical results, mCARMEN correctly detected viral nucleic acids 95% (130/137) of the  
365 time. For specimens that were evaluated concurrently, mCARMEN and the comparator  
366 assay had 9 discordant results (128/137) with equivalent sensitivity for all but the HMPV  
367 specimens; BioFire did not detect virus in 3 specimens (1 FLUAV, 1 FLUBV, and 1



368 HRSV) and mCARMEN did not detect virus in 6 specimens (1 FLUAV, 1 FLUBV, 1  
369 HRSV, and 3 HMPV). Both mCARMEN and BioFire identified 5 specimens with co-  
370 infections (HCoV-NL63 in a FLUAV specimen, HPIV-3 in a FLUBV specimen, HCoV-  
371 HKU-1 in 2 HRSV specimens, and HCoV-NL63 in a HRSV specimen). Together with  
372 the original clinically detected co-infection, there were 6 (1.1%) co-infections in our  
373 specimen set (Extended Data Fig. 7c). Overall, mCARMEN and BioFire were 99.4%  
374 (1485/1494 individual tests) concordant (Fig. 3e, Extended Data Fig. 9). For the  
375 contrived samples, mCARMEN correctly identified 99% (148/150) (Fig. 3e).

376  
377 We used unbiased metagenomic NGS to further evaluate 9 discordant specimens (2  
378 FLUAV, 2 FLUBV, 2 HRSV, and 3 HMPV), generating an average of 13 million reads  
379 per specimen. Either no viral reads were present by NGS or partial genomes were  
380 assembled, but the RVP amplicon was missing, making it unlikely for our assay to  
381 return a positive result (Extended Data Fig. 9, Supp. Table 3). Based on these results  
382 and our previous NGS testing, which indicated NGS was not as sensitive as RVP or the  
383 comparator assays, we cannot determine the viral positivity status of these specimens.

### 384 385 **Allelic discrimination distinguishes between SARS-CoV-2 variant lineages of** 386 **concern**

387  
388 Since current clinical diagnostics are not well positioned to identify mutations - single  
389 nucleotide polymorphisms (SNPs), insertions, or deletions - carried in SARS-CoV-2  
390 variant lineages<sup>1,22,23</sup>, we wanted to develop a single platform with both diagnostic and  
391 surveillance capabilities for comprehensive detection of 26 SARS-CoV-2 spike gene  
392 mutations. We selected these 26 mutations to distinguish between or to detect  
393 mutations shared amongst the Alpha, Beta, Gamma, Delta, Epsilon, Lambda, and  
394 Omicron variant lineages (Table 1; B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/9, C.37,  
395 and B.1.1.529 using PANGO nomenclature system, respectively)<sup>8</sup>, and then used a  
396 generative sequence design algorithm (manuscript in prep.) to produce crRNAs for  
397 allelic discrimination.

398  
399 With the continuous emergence of mutations that can lead to increased transmissibility  
400 or enhanced virulence, we also wanted to greatly streamline assay generation for each  
401 new SARS-CoV-2 mutation or variant. Thus, we developed an easily adaptable method  
402 to track these changes that we call the mCARMEN variant identification panel (VIP).  
403 VIP has two non-overlapping primer pair sets within conserved regions of the spike  
404 gene to amplify the full-length sequence for use with any crRNA pair. These 26 crRNA  
405 pairs, individually or in combination, allow us to track existing variants as well as identify  
406 emerging variants, such as Omicron (Fig. 4a). Initially, we tested over 60 combinations  
407 of crRNAs on unamplified synthetic material to identify the crRNA pairs with the largest  
408 fluorescence ratio for expected divided by unexpected signal at each mutation  
409 (Extended Data Fig. 10).

410  
411 We validated the flexible VIP method by testing RNA extracted from SARS-CoV-2 viral  
412 seed stocks, for the ancestral (Washington isolate: USA-WA1, ATCC) lineage, and  
413 Alpha, Beta, Gamma, Delta, and Epsilon lineages (Fig. 4b, Extended Data Fig. 11). As

414 expected, the WA SARS-CoV-2 viral seed stock isolate showed ancestral signals for all  
415 mutations tested. Alpha, Beta, Gamma, Delta, and Epsilon had expected signals for  
416 every mutation confirmed by NGS (Table 1, description in methods). Though each  
417 crRNA has different kinetics owing to varying hit-calling thresholds, we almost always  
418 observed a higher expected signal above the unexpected signal, which is important in  
419 the prevention of false positive results (Extended Data Fig. 12).

420

421 For clinical relevance, we developed an automated variant calling procedure that  
422 evaluates the mutation-specific signal in SARS-CoV-2-positive patient specimens and  
423 returns a variant lineage result (Extended Data Fig. 13a, described in methods). For  
424 some mutations at the same or similar genomic position we observed cross-reactive  
425 signals which we overcame by comparing the maximum fluorescent ratios between  
426 those mutations and assigning the positive call to the higher of the two (Extended Data  
427 Fig. 13b).

428

429 We applied VIP and the analysis pipeline to identify the variant lineage in 106 known  
430 SARS-CoV-2-positive patient specimens: 24 Alpha, 23 Beta, 24 Gamma, 6 Delta, and  
431 24 Epsilon, and 5 presumptive Omicron specimens. Of the 101 specimens with NGS  
432 results, excluding Omicron specimens, all but 3 (97%) specimens (1 Beta and 2  
433 Gammas) were given the correct variant lineage identification (Fig. 4c&d, Extended  
434 Data Fig. 13c, Supp. Table 3). The Beta specimen had signal for a Beta-specific SNP,  
435 K417N, but also had signal for E154K, a Delta-specific SNP. The Gamma specimens  
436 had no unique signals and shared signals for mutations overlapping with the Beta  
437 lineage resulting in a “Variant not Identified” call. The 5 presumed Omicron specimens  
438 had S gene drop-out by TaqPath RT-qPCR and were found to have the following  
439 mutations by mCARMEN: del69/70, K417N, S477N, T478K, N501Y, and D614G (Fig.  
440 4d). mCARMEN is able to return a result within a few hours while NGS takes several  
441 days thus we are still awaiting the results for final comparison.

442

443

444 Focusing on the results for the individual mutations themselves, we found that only 2  
445 mutations, E154K and E484K, had more than 5 specimens differ in their results  
446 between NGS and VIP (Fig. 4e). E154K had 19 differences, all for Epsilon specimens,  
447 while E484K had 7 differences. Since all Epsilon specimens contain a SNP 2 amino  
448 acids away from E154, we believe the E154K crRNA is detecting the Epsilon W152C  
449 mutation, which would account for all 19 discrepancies between NGS and VIP.  
450 Meanwhile the 7 E484K discrepancies are likely attributed to our comparison of cross-  
451 reactive signals between E484K and T478K, thus new crRNA designs are likely needed  
452 to optimally differentiate these signals. Altogether, we found VIP had 97.9%  
453 concordance to NGS at allelic discrimination.

454

### 455 **Quantification of viral genomic copies in samples using Cas12 and Cas13** 456 **reaction kinetics**

457

458 Similar to widely-used multiplexed approaches, like BioFire<sup>sz</sup>, the original design of  
459 CARMEN<sup>sz</sup> did not provide a true quantitative assessment of viral genome copies

460 present in a sample. Establishing the total viral quantity in a patient is important for  
461 assessing the stage of infection, transmission risk, and most effective treatment plan<sup>9,10</sup>.  
462 The gold standard assay for sample quantification, RT-qPCR, leverages the standard  
463 curve - serial dilutions of a given target at a known concentration - as a means of using  
464 Ct values to approximate viral quantity<sup>4</sup>. We wanted to determine if a similar approach  
465 could be applied to mCARMEN.

466  
467 To make mCARMEN quantitative, we took advantage of the existence of multiple  
468 CRISPR/Cas proteins with differing reaction kinetics and enzymatic activities, and the 3  
469 fluorescent channels detected by the Fluidigm Biomark (Fig. 5a). We incorporated DNA-  
470 targeting CRISPR/Cas12 into the Cas13 reaction, and used protein-specific reporters in  
471 different fluorescent channels, HEX and FAM, respectively to maximize our multiplexing  
472 capabilities. To capture reaction kinetics, images of the IFC chip are taken every 5  
473 minutes for 3 hours to generate sigmoidal curves from the fluorescent signals over time.  
474 When considering enzymatic activities, Cas13 has enhanced sensitivity compared to  
475 Cas12 since the process of reverse transcribing the dsDNA sample input for Cas13  
476 detection results in increased starting concentration. Thus, we use Cas12 to capture the  
477 kinetic curves of higher copy material on the standard curve and Cas13 to capture lower  
478 copy material.

479  
480 We integrated our quantification efforts into RVP, since this assay was extensively  
481 evaluated in both research and clinical settings. We manually designed Cas12 crRNAs  
482 in the same region of the viral genome that the RVP Cas13 crRNAs target for a two-  
483 step standard curve generation on the same target amplicon for Cas12- and Cas13-  
484 RNPs individually. The first step requires plotting the fluorescence for a range of  
485 concentrations (Cas12:  $10^7$ - $10^9$  copies/ $\mu$ L; Cas13:  $10^3$ - $10^6$  copies/ $\mu$ L) at each time point  
486 to calculate the  $IC_{50}$  through a sigmoidal, four parameter logistic (4PL) curve,  $R^2 > 0.9$   
487 (Fig. 5b, Extended Data Fig. 14a&b). In some cases, we could not determine the  $IC_{50}$   
488 value because signal saturation occurred too quickly or not at all and therefore, that  
489 concentration was excluded from analysis. In the second step, we plotted the  $IC_{50}$  values  
490 onto a semilog line, where concentration is logarithmic and time is linear, to generate  
491 the standard curves (Fig. 5c). We compared these results to a standard curve  
492 generated from RT-qPCR using the same serial dilutions and found a linear relationship  
493 between SARS-CoV-2 and FLUAV  $IC_{50}$  values to Ct values ( $R^2$  0.901 and 0.881,  
494 respectively) (Fig. 5d). In all, these results suggest that by using Cas12 and Cas13 in  
495 combination, we could extrapolate viral quantification - spanning a  $10^3$ - $10^6$  range of  
496 target concentrations - from patient specimens with performance similar to RT-qPCR.

## 498 Discussion

499  
500 Here, we report mCARMEN, a high-throughput, multiplexed, and microfluidic diagnostic  
501 and surveillance platform with panels for respiratory viruses and SARS-CoV-2 variants  
502 that can be parallelized to test 300-550 patient specimens in an 8 hour working day. To  
503 make mCARMEN a clinically relevant technology, we built on CARMEN v1<sup>37</sup> by  
504 streamlining the workflow and incorporating commercially available Fluidigm  
505 instrumentation<sup>38</sup>. We validated mCARMEN on 902 patient specimens for the detection

506 of 9-21 human respiratory viruses (RVP) or SARS-CoV-2 variant mutations (VIP) with  
507 high concordance to comparator assays which passed the FDA's performance criteria<sup>43</sup>  
508 for all but one virus. Notably, when testing previously positive clinical specimens, we  
509 found a substantial proportion were not positive by concurrent testing, but were positive  
510 by mCARMEN (Fig. 2). This suggests sample degradation issues - a known problem  
511 when detecting RNA viruses in clinical specimens<sup>41,45</sup> - that mCARMEN is more robust to  
512 handling than RT-qPCR or NGS. Though we cannot rule out false positives, we did not  
513 detect SARS-CoV-2 in specimens prior to the pandemic and we had 100% concordance  
514 with true virus-negative specimens.


515  
516 To enhance mCARMEN's clinical diagnostic relevance and meld it with surveillance  
517 technology requirements, we further maximized its multiplexing capabilities by  
518 discriminating between mutations for variant lineage classification in patient specimens  
519 and quantifying viral genomic copies. Currently, variant lineage classification is only  
520 evaluated by NGS, which is costly and relies on specialized expertise found outside the  
521 clinic<sup>22,24</sup>. VIP gives similarly rich information about key SARS-CoV-2 mutations at 5-10x  
522 cheaper, per sample, than NGS, and is far more comprehensive than current nucleic  
523 acid-based diagnostics. Importantly, VIP was poised to differentiate Omicron  
524 immediately as it emerged since we routinely design guides to preemptively identify  
525 mutations of interest in the spike gene in preparation for emerging variants. Given the  
526 number of mutations detected by VIP, we expect to observe distinct mutation signatures  
527 between variant lineages that will allow us to differentiate these and future variants of  
528 concern from each other without assay redesign. We also adapted mCARMEN for dual  
529 Cas12 and Cas13 detection by capitalizing on the differing protein kinetics. A few  
530 groups have studied Cas12 and Cas13 reaction kinetics to inform assay  
531 quantification<sup>46,47</sup>, but the range of concentrations being quantified has been limited due  
532 to reaction saturation. We expanded the quantifiable concentration range to 5-6 orders  
533 of magnitude, which is similar to RT-qPCR. These mCARMEN applications have the  
534 potential to provide a more holistic diagnosis to the patient.

535  
536 We rapidly developed mCARMEN for use in the pandemic, but faced challenges during  
537 the clinical validation and approval process needed for a large-scale roll-out.  
538 Specifically, it was difficult to obtain at least 30 previously confirmed clinical specimens  
539 for each virus on RVP with enough material available for extensive concurrent testing,  
540 while also facing specimen degradation issues that inevitably occur over time.  
541 mCARMEN's performance exceeded FDA requirements, yet the FDA was unable to  
542 give it full emergency use authorization (EUA) review and approval because of their  
543 limited bandwidth and need to prioritize other applications. Lastly, funding to support  
544 mCARMEN in clinics and beyond has been scarce despite there being a clear need for  
545 it.

546  
547 Although further work would be required to bring mCARMEN fully to the clinic,  
548 mCARMEN can function as an ideal single technology platform with diagnostic and  
549 surveillance capabilities for detecting respiratory pathogens and variants. We have  
550 taken significant steps to streamline assay workflow while enhancing sensitivity and not  
551 sacrificing specificity. There is currently no other diagnostic technology that combines

552 multiplexed pathogen testing with variant tracking and is highly scalable and amenable  
553 to clinical laboratory settings. This technology has the potential to test for other  
554 infectious diseases<sup>48</sup> and sample types for an even more comprehensive, multiplexed,  
555 and high-throughput diagnostic, all while maintaining a level of clinical relevance that is  
556 unmatched to other nucleic acid- or antigen-based diagnostics.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




557  
558  
559  
560

**Figure 1. CARMEN implementation on Fluidigm achieves greater sensitivity quicker.** **a**, Schematic of CARMEN v1 (top) and mCARMEN (bottom) workflows. **b**, Heatmap showing mCARMEN fluorescent data across 21 human respiratory viruses

561 that were amplified using two separate primer pools. Synthetic DNA fragments were  
562 serially diluted from  $10^3$ - $10^1$  copies/ $\mu$ L and added to Q5 amplification master mix. All  
563 samples were background subtracted from NTC-noMg negative control. **c**,  
564 Concordance between CARMEN v1 and mCARMEN from **b**. Blue: targets at  $10^3$   
565 copies/ $\mu$ L; green: targets at  $10^2$  copies/ $\mu$ L; red: targets at  $10^1$  copies/ $\mu$ L. **d**,  
566 Fluorescence kinetics of amplified SARS-CoV-2 DNA gene fragments from  $10^4$ - $10^1$   
567 copies/ $\mu$ L at 0, 60, and 180 minutes post-reaction initiation. Blue: mCARMEN; red:  
568 CARMEN v1. **e**, Testing 21 human respiratory virus panel on clinical specimens from 6  
569 SARS-CoV-2 positive, 4 SARS-CoV-2 negative NP swabs, and 8 FLUAV positive  
570 specimens, collected prior to Dec. 2019, and 5 no target controls (NTCs). Heatmap  
571 shows fluorescent signals from SARS-CoV-2 crRNA, FLUAV crRNA and no crRNA  
572 control. Blue: mCARMEN; red: CARMEN v1. **f**, Concordance of mCARMEN and NGS  
573 on 58 suspected respiratory virus infected patient specimens collected prior to Dec.  
574 2019. Black: detected by both mCARMEN and NGS; blue: detected by mCARMEN  
575 only; green: detected by NGS only. mCARMEN values are shown as normalized  
576 fluorescence, FAM signal divided by passive reference dye, ROX, signal at 1 hour post-  
577 reaction initiation. CARMEN v1 values are shown as raw fluorescence, FAM signal at 3  
578 hours. NTC, no target control; NTC-extract, no target control taken through extraction,  
579 cDNA synthesis, amplification, and detection; NTC-cDNA, no target control taken  
580 through cDNA synthesis, amplification, and detection; NTC-amp, no target control taken  
581 through amplification and detection; NTC-det, no target control taken through detection;  
582 NTC-noMg, no target control expected to have no fluorescent signal due to lack on  
583 Mg<sup>2+</sup> needed to activate Cas13.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




584  
 585 **Figure 2. Automated and condensed mCARMEN workflow evaluated on >500 NP**  
 586 **swabs.** **a**, Schematic of streamlined mCARMEN workflow to test 188 patient specimens  
 587 for a panel of 9 human respiratory viruses, RVP (SARS-CoV-2, HCoV-HKU1, HCoV-  
 588 OC43, HCoV-NL63, FLUAV, FLUBV, HPIV-3, HRSV, HMPV) and a human internal  
 589 control (RNase P). **b**, Concordance of RVP and RT-qPCR results; RT-qPCR results  
 590 from concurrent testing (top), and RT-qPCR results from original testing (bottom). **c**,  
 591 Scaled normalized fluorescence at 1 hour for 533 NP swabs ranked by increasing  
 592 SARS-CoV-2 signal (blue) with the respective RNase P signal (gray). Fluorescence is  
 593 normalized by dividing the FAM signal by ROX then data are scaled from 0 to 1. NTC-  
 594 noMg signal as 0 and the maximum normalized fluorescence value at 1 hour as 1.  
 595 Dashed horizontal line: threshold for RVP positivity. Threshold is calculated by  
 596 multiplying the NTC-extract fluorescence value by 1.8; NTC-extract: no template control




597 taken through the entire workflow. Gray X represents the single failed sample excluded  
598 from concordance calculations and other analysis. **d**, Scatter plot of the scaled  
599 normalized fluorescence values from **b** compared to viral Ct values obtained from  
600 concurrent testing with the ThermoFisher TaqPath COVID-19 Kit. Green: positive  
601 SARS-CoV-2 signal detected by both RVP and RT-qPCR; gray: inconclusive RT-qPCR  
602 result indicating one or two of the three technical replicates were undetermined; black:  
603 undetermined RT-qPCR result indicating all three technical replicates were negative for  
604 SARS-CoV-2. Dashed horizontal lines: threshold for RVP positivity. Dashed vertical line:  
605 Ct value of 37 (FDA positivity cutoff). **e**, Concordance of RVP scaled normalized  
606 fluorescence values and SARS-CoV-2 read counts by unbiased NGS. Dashed  
607 horizontal line: threshold for RVP positivity; dashed vertical line: 10 reads mapped to the  
608 SARS-CoV-2 genome by NGS, threshold for NGS positivity. Blue: SARS-CoV-2 N1 RT-  
609 qPCR Ct < 25; green: Ct > 25; black: negative by RT-qPCR. **f**, Normalized fluorescence  
610 values at 1 hour for 11 patient specimens.


611  
612  
613  
614  
615  
616  
617  
618



619  
 620 **Figure 3. Clinical evaluation of RVP at CLIA-certified laboratory in Massachusetts**  
 621 **General Hospital. a**, Workflow of limit of detection (LOD) studies following the FDA  
 622 guidelines for establishing assay sensitivity. **b**, Fluorescent values for SARS-CoV-2  
 623 target LOD at multiple concentrations, 5,000, 2,500, 1,000, and 500 copies/mL for 20  
 624 replicates. **c**, Normalized fluorescence for each virus on RVP evaluated against on-  
 625 target sequence, closely related sequences (Supp. Table 2), and a no target control,  
 626 NTC to establish assay specificity. **d**, Positive percent and negative percent agreement  
 627 (PPA, NPA, respectively) for each virus on RVP calculated based on clinical data in  
 628 Supp. Table 3. **e**, Concordance of RVP to concurrent comparator assays for the 166  
 629 retrospective patient specimens tested (left) and concordance of RVP to contrived  
 630 samples (right).



631  
 632 **Figure 4. SARS-CoV-2 variant identification using SNP determining Cas13-crRNA**  
 633 **combinations.** **a**, Schematic of SARS-CoV-2 mutation - SNP or deletion  
 634 within the spike gene using highly specific Cas13 crRNA designs. **b**, SARS-CoV-2 viral  
 635 seed stocks from ancestral (WA), Alpha, Beta, Gamma, Delta, or Epsilon variant  
 636 lineages ( $10^6$  copies/mL) amplified by 2 primer pairs and tested for the presence or  
 637 absence of spike gene mutations. Data shown as the  $\log_2$  of the maximum crRNA  
 638 fluorescence ratio at any time point up to 180 minutes. The ratio that reached maximum  
 639 fastest is plotted as either ancestral/mutation (blue, negative) or mutation/ancestral  
 640 (purple, positive). \* indicates the particular mutation was confirmed by NGS. **c**,  
 641 Comparison of 106 SARS-CoV-2 positive variant patient specimens by mCARMEN and  
 642 NGS based on the final variant call assessed by unique combinations of mutations  
 643 (Methods Variant Calling). Black: both VIP and NGS; Yellow: NGS only; Green: VIP  
 644 only. **d**, 106 variant patient specimens tested for various SNPs by mCARMEN are  
 645 organized by Alpha, Beta, Gamma, Delta, or Epsilon. Data shown as the  $\log_2$  maximum  
 646 crRNA fluorescence ratio of mutation/ancestral (positive) or ancestral/mutation  
 647 (negative) at any time point up to 180 minutes focusing on the Omicron mutations.  
 648 Ancestral  $<0$ , derived  $>0$ , dashed line at 0 for reference. **e**, Individual mutation  
 649 breakdown of mCARMEN results to NGS on 106 variant patient specimens. Black:  
 650 mutations shared by both VIP and NGS; Yellow: NGS only; Green: VIP only; Gray:  
 651 ancestral for VIP and NGS.



652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671

**Figure 5. Viral quantification in samples with RVP using both Cas12 and Cas13 in combination.** **a**, Schematic of Cas12 and Cas13 dual detection on mCARMEN to quantify viral copy number in samples. Similar to RT-qPCR, standard curves are utilized for assay quantification. Cas12 captures higher copy material while Cas13 captures lower copy material. Fluorescence is plotted over time to determine the IC<sub>50</sub> value at each concentration using a sigmoidal 4PL fit. The IC<sub>50</sub> values are then plotted by concentration to generate a semilog line with an R<sup>2</sup> value >0.8 for Cas12 and Cas13 individually. After line generation, the IC<sub>50</sub> value of each patient sample is plotted onto these lines to determine viral copies/μL. **b**, Normalized fluorescence ratio of Cas13-crRNA (top) or Cas12-crRNA (bottom) signal over time at varying concentrations of synthetic SARS-CoV-2 Orf1ab RNA. **c**, Semilog lines generated by IC<sub>50</sub> values from Cas12 and Cas13 crRNA signals, and Ct values from RT-qPCR for >4 target concentrations of SARS-CoV-2 and FLUAV IVT RNA. Blue: Cas13; Orange: Cas12; Gray: RT-qPCR. **d**, Linear regression to compare mCARMEN IC<sub>50</sub> values to RT-qPCR Ct values with a best line fit shown as a dashed line. Black: SARS-CoV-2; Gray: FLUAV.

672 **Author Contributions:**

673 N.L.W. and C.M. initially conceived this study then involved C.M.A., S.G.T., and J.W. for  
674 preliminary implementation. N.L.W., M.Z., J.W., C.M.A., S.G.T., M.W.T., J.K. set up 21  
675 respiratory virus testing on CARMEN v1. N.L.W. and S.M. designed the primers and  
676 crRNAs for the 21 respiratory viruses tested on CARMEN v1 and mCARMEN. N.L.W.,  
677 J.W., C.M.A., S.G.T. performed initial experiments on Fluidigm instrumentation. M.Z.,  
678 J.W., C.M.A. wrote the python scripts for mCARMEN data analysis. N.L.W. performed  
679 experiments to streamline the mCARMEN workflow with help from C.H., J.W., and  
680 S.G.T. N.L.W., C.H., MM conducted the SARS-CoV-2 patient sample testing in an  
681 academic setting, B.L.M. and F.C. helped obtain these samples. C.H., E.M.M., B.M.S.,  
682 J.E., D.B., G.M. performed clinical evaluation of mCARMEN RVP at MGH, under  
683 guidance from N.L.W., J.J., J.E.L., E.R., J.A.B., C.M. J.W. wrote and generated the  
684 software used for RVP. N.L.W. with help from M.R.B. conducted NGS on patient  
685 samples. N.L.W. designed and tested the primers for VIP, and N.L.W. and S.M.  
686 designed the crRNAs for VIP. N.L.W. conducted the experimental validation of VIP.  
687 M.K.K., M.W.W., M.W.K., and J.R.B. provided FLUAV samples, SARS-CoV-2 VOC  
688 seed stocks, and SARS-CoV-2 VOC patient samples and the corresponding NGS data.  
689 K.J.S. provided assistance in patient specimen collection. M.S., S.J., M.L.C. provided  
690 Omicron specimens. N.L.W. tested all SARS-CoV-2 VOC specimens by mCARMEN.  
691 M.Z. wrote and generated the VOC calling analysis pipeline for VIP testing under  
692 guidance from N.L.W. N.L.W. conducted experiments to make mCARMEN quantitative  
693 with assistance from T.G.N. K.J.S., B.L.M., C.T.H., D.T.H., J.E.L., J.R.B., E.R., J.A.B.,  
694 P.C.B., P.C.S., C.M. provided insights into the work overall. N.L.W. generated the  
695 figures with help from M.Z. and J.W. N.L.W. wrote the paper with help from C.H. and  
696 guidance from P.C.S. and C.M. J.A.B., P.C.B., P.C.S., and C.M. jointly supervised the  
697 work. All authors reviewed the manuscript.

698  
699 **Acknowledgements:**

700 We would like to thank the Blainey Lab and Hung Lab at the Broad Institute for  
701 providing additional laboratory space to perform the work; M. Kirby, M. Wilson, M.  
702 Keller, J. Barnes for providing FLUAV samples, SARS-CoV-2 variant seed stocks, and  
703 SARS-CoV-2 variant patient samples and the corresponding NGS data. J. Arizti Sanz,  
704 Y. Zhang, and A. Bradley for helping with guide design or sharing reagents; G. Adams,  
705 S. Dobbins, K. DeRuff and other members of the Sabeti Lab COVID-19 sequencing  
706 team for providing patient samples; L. Krasilnikova, C. Tomkins-Tinch, C. Loreth, and  
707 other Sabeti Lab members for providing assistance with NGS analysis on Terra; B.  
708 Zhou for helping provide the SARS-CoV-2 VOC seed stocks and patient samples; H.  
709 Metsky, C. Freije, J. Arizti Sanz, S. Siddiqui for their thoughtful discussions and reading  
710 of the manuscript. Funding was provided by DARPA D18AC00006. This work is made  
711 possible by support from Flu lab and a cohort of generous donors through TED's  
712 Audacious Project, including the ELMA Foundation, MacKenzie Scott, the Skoll  
713 Foundation, and Open Philanthropy. Funding for NGS was provided by Centers for  
714 Disease Control and Prevention COVID-19 baseline genomic surveillance contract  
715 sequencing (75D30121C10501 to Clinical Research Sequencing Platform, LLC), a CDC  
716 Broad Agency Announcement (75D30120C09605 to B.L.M), National Institute of Allergy  
717 and Infectious Diseases (U19AI110818 to P.C.S). C.M. is supported by start-up funds

718 from Princeton University. M.Z. and M.W.T. were supported by the National Science  
719 Foundation Graduate Research Fellowship under Grant No. 1745302. B.A.P. is  
720 supported by the National Institute of General Medical Sciences grant T32GM007753.

721  
722  
723 The views, opinions, conclusions, and/or findings expressed should not be interpreted  
724 as representing the official views or policies, either expressed or implied, of the  
725 Department of Defense, US government, National Institute of General Medical  
726 Sciences, DHS, or the National Institutes of Health. The DHS does not endorse any  
727 products or commercial services mentioned in this presentation. In no event shall the  
728 DHS, BNBI or NBACC have any responsibility or liability for any use, misuse, inability to  
729 use, or reliance upon the information contained herein. In addition, no warranty of  
730 fitness for a particular purpose, merchantability, accuracy or adequacy is provided  
731 regarding the contents of this document. The United States Government retains and the  
732 publisher, by accepting the article for publication, acknowledges that the United States  
733 Government retains a non-exclusive, paid up, irrevocable, world-wide license to publish  
734 or reproduce the published form of this manuscript, or allow others to do so, for United  
735 States Government purposes.

736  
737 The findings and conclusions in this report are those of the authors and do not  
738 necessarily represent the official position of the Centers of Disease Control and  
739 Prevention (CDC). Use of trade names and commercial sources is for identification  
740 purposes only and does not imply endorsement.

741  
742 **Competing Interests Statement**

743 N.L.W., S.G.T., C.M.A., D.T.H., P.C.B., P.C.S., and C.M. are co-inventors on a patent  
744 related to this work. P.C.B is a co-inventor on patent applications concerning droplet  
745 array technologies and serves as a consultant and equity holder of companies in the  
746 microfluidics and life sciences industries, including 10x Genomics, GALT, Celsius  
747 Therapeutics, Next Generation Diagnostics, Cache DNA, and Concerto Biosciences;  
748 P.C.B's laboratory receives funding from industry for unrelated work. P.C.S. is a co-  
749 founder of and consultant to Sherlock Biosciences and a Board Member of Danaher  
750 Corporation, and holds equity in the companies.

751  
752 **Code availability**

753 The code used for data analysis in this study is made available on Github:  
754 <https://github.com/broadinstitute/mcarmen>.

755  
756 **Data availability**

757 All requests for raw and analyzed data and materials will be reviewed by the Broad  
758 Institute of Harvard and MIT to verify if the request is subject to any intellectual property  
759 or confidentiality obligations. Data and materials that can be shared will be released via  
760 a Material Transfer Agreement. RNA sequencing data will be made available upon  
761 request for academic use and within the limitations of the provided informed consent by  
762 the corresponding author upon acceptance. Source code is available on github:  
763 <https://github.com/broadinstitute/mcarmen>.

764

## 765 **Reporting summary**

766 Further information on research design is available in the Nature Research Reporting  
767 Summary linking to this article.

768

## 769 **Methods**

770

### 771 **1. Patient samples / ethics statement**

772 Use of clinical excess of human specimens from patients with SARS-CoV-2 from the  
773 Broad Institute's Genomics Platform CLIA Laboratory was approved by the MIT IRB  
774 Protocol #1612793224. Additional SARS-CoV-2 samples were collected from  
775 consented individuals under Harvard Longwood Campus IRB #20-1877 and covered by  
776 an exempt determination (EX-7295) at the Broad Institute. Other human-derived  
777 samples from patients with SARS-CoV-2 were collected by the CDC and determined to  
778 be non-human subjects research; the Broad Office of Research Subject Protections  
779 determined these samples to be exempt. Human specimens from patients with SARS-  
780 CoV-2, HCoV-HKU1, HCoV-NL63, FLUAV, FLUBV, HRSV, and HMPV were obtained  
781 under a waiver of consent from the Mass General Brigham IRB Protocol  
782 #2019P003305. Researchers at Princeton were determined to be conducting not-  
783 engaged human subjects research by the Princeton University IRB.

784

### 785 **2. General mCARMEN Procedures**

#### 786 **2a. Preparation and handling of synthetic materials**

787 crRNAs were synthesized by Integrated DNA Technologies (Coralville, IA),  
788 resuspended in nuclease-free water to 100  $\mu$ M, and further diluted for input into the  
789 detection reaction. Primer sequences were ordered from Eton or Integrated DNA  
790 Technologies, resuspended in nuclease-free water to 100  $\mu$ M, and further combined at  
791 varying concentrations for pooled amplification.

792

#### 793 **2b. Preparation of *in vitro* transcribed (IVT) material**

794 DNA targets were ordered from Integrated DNA Technologies and *in vitro* transcribed  
795 (IVT) using the HiScribe T7 High Yield RNA Synthesis Kit (New England Biolabs, NEB).  
796 Transcriptions were performed according to the manufacturer's recommendations with a  
797 reaction volume of 20  $\mu$ L that was incubated overnight at 37°C. The transcribed RNA  
798 products were purified using RNAClean XP beads (Beckman Coulter) and quantified  
799 using NanoDrop One (Thermo Scientific). Depending on the experiment, the RNA was  
800 serially diluted from  $10^{11}$  down to  $10^{-3}$  copies/ $\mu$ L and used as input into the amplification  
801 reaction.

802

#### 803 **2c. Extraction - Manual or Automated**

804 RNA was manually extracted from input material using the QIAamp Viral RNA Mini Kit  
805 (QIAGEN) according to the manufacturer's instructions. RNA was extracted from 140  $\mu$ L  
806 of input material with carrier RNA and samples were eluted in 60  $\mu$ L of nuclease free  
807 water and stored at -80 °C until use. RNA was automatically extracted using the  
808 MagMAX™ DNA Multi-Sample Ultra 2.0 Kit on a KingFisher™ Flex Magnetic Particle  
809 Processor with 96 Deep-Well Head (Thermo Fisher Scientific). RNA was extracted from

810 200  $\mu$ L of input material and was run according to the “Extract RNA - Automated  
811 method (200- $\mu$ L sample input volume)” protocol in [TaqPath™ COVID-19 Combo Kit](#)  
812 [Protocol](#), on page 21-24. The MVP\_2Wash\_200\_Flex protocol was used. Samples were  
813 eluted in 50  $\mu$ l of elution solution and either directly added to the amplification reaction  
814 or stored at  $-80^{\circ}\text{C}$  until use.

815

## 816 **2d. Amplification: Qiagen or SSIV**

817 We followed the CARMEN v1 platform for two-step reverse transcription amplification  
818 then transitioned to a single-step amplification reaction after experiments depicted in  
819 Figure 1. We used the Qiagen OneStep RT-PCR Mix for Figures 2,3,5 and Invitrogen  
820 SuperScript IV One-Step RT-PCR System for Figure 4. For the Qiagen OneStep RT-  
821 PCR, a total reaction volume of 50  $\mu$ L was used with some modifications to the  
822 manufacturers recommended reagent volumes. Specifically 1.25X final concentration of  
823 OneStep RT-PCR Buffer, 2x more Qiagen Enzyme Mix, and 20% RNA input. Final  
824 concentrations for all viral primers were 300 nM and 100 nM for RNase P primers. The  
825 following thermal cycling conditions were used: (1) reverse transcription at  $50^{\circ}\text{C}$  for 30  
826 min; (2) initial PCR activation at  $95^{\circ}\text{C}$  for 15 min; (3) 40 cycles of  $94^{\circ}\text{C}$  for 30 s,  $58^{\circ}\text{C}$  for  
827 30 s, and  $72^{\circ}\text{C}$  for 30 s. For Invitrogen SuperScript IV One-Step RT-PCR, a total  
828 reaction volume of 25  $\mu$ L with 20% RNA input and final primer concentrations at 1  $\mu$ M.  
829 The following thermal cycling conditions were used: (1) reverse transcription at  $50^{\circ}\text{C}$  for  
830 10 min; (2) initial PCR activation at  $98^{\circ}\text{C}$  for 2 min; (3) 35 cycles of  $98^{\circ}\text{C}$  for 10 s,  $60^{\circ}\text{C}$   
831 for 10 s, and  $72^{\circ}\text{C}$  for 1 min 30 s; (4) final extension at  $72^{\circ}\text{C}$  for 5 min. See Supp.  
832 Table 2 for information on primer sequences used in each mCARMEN panel.

833

## 834 **2e. Fluidigm Detection**

835 The Cas13 detection reactions were made into two separate mixes: assay mix and  
836 sample mix, for loading onto a microfluidic IFC (depending on the experiment, either  
837 Gene Expression (GE) or Genotyping (GT) IFCs were used in either a 96.96 or 192.24  
838 format) (Fluidigm):

839 The *assay mix* contained LwaCas13a (GenScript) and on occasion LbaCas12a (NEB)  
840 concentration varied with experiment, 1 $\times$  Assay Loading Reagent (Fluidigm), 69U T7  
841 polymerase mix (Lucigen), and crRNA concentration varied with experiment for a total  
842 volume of 16  $\mu$ L per reaction. See below for details pertaining to each mCARMEN  
843 panel.

844 The *sample mix* contained 25.2U RNase Inhibitor (NEB), 1 $\times$  ROX Reference Dye  
845 (Invitrogen), 1 $\times$  GE Sample Loading Reagent (Fluidigm), 1 mM ATP, 1 mM GTP, 1 mM  
846 UTP, 1 mM CTP, 9 mM  $\text{MgCl}_2$  in a nuclease assay buffer (40 mM Tris-HCl pH 7.5, 1  
847 mM DTT) and either a 500 nM quenched synthetic fluorescent RNA reporter  
848 (FAM/rUrUrUrUrUrUrU/3IABkFQ/ or VIC/rTrTrArTrTrArTrT/3IABkFQ/ Integrated DNA  
849 Technologies) or RNaseAlert v2 (Invitrogen) was used for a total volume of 12.6  $\mu$ L.  
850 See below for details on each mCARMEN panel.

851

852 *IFC Loading and Run:* Syringe, Actuation Fluid, Pressure Fluid (Fluidigm), and 4  $\mu$ L of  
853 assay or sample mixtures were loaded into their respective locations on a microfluidic  
854 IFC (depending on the experiment, either Gene Expression (GE) or Genotyping (GT)  
855 IFCs were used in either a 96.96 or 192.24 format) and were run according to the



856 manufacturer's instructions. The IFC was loaded onto the IFC Controller RX or Juno  
857 (Fluidigm) where the 'Load Mix' script was run. After proper IFC loading, images over  
858 either a 1-3 hour period were collected using a custom protocol on Fluidigm's EP1 or  
859 Biomark HD.

860

## 861 **2h. Fluidigm Data Analysis**

862 We plotted reference-normalized background-subtracted fluorescence for guide-target  
863 pairs. For a guide-target pair (at a given time point,  $t$ , and target concentration), we first  
864 computed the reference-normalized value as  $(\text{median}(P_t - P_0) / (R_t - R_0))$  where  $P_t$  is the  
865 guide signal (FAM) at the time point,  $P_0$  is its background measurement before the  
866 reaction,  $R_t$  is the reference signal (ROX) at the time point,  $R_0$  is its background  
867 measurement, and the median is taken across replicates. We performed the same  
868 calculation for the no template (NTC) control of the guide, providing a background  
869 fluorescence value for the guide at  $t$  (when there were multiple technical replicates of  
870 such controls, we took the mean value across them). The reference-normalized  
871 background-subtracted fluorescence for a guide-target pair is the difference between  
872 these two values.

873

## 874 **3. 21 Respiratory Viruses (Fig. 1)**

### 875 **3ai. Design**

876 The oligonucleotide primers and CRISPR RNA guides (crRNAs) are designed for  
877 detection of conserved regions of the following respiratory viruses: SARS-CoV-2,  
878 HCoV-229E, HCoV-HKU1, HCoV-NL63, HCoV-OC43, FLUAV, FLUBV, HMPV, HRSV,  
879 HPIV-1,2,3,4, AdV, HEV-A,B,C,D, SARS-CoV, MERS-CoV, and HRV. More specifically,  
880 complete genomes for all viruses on the panel were downloaded from NCBI and aligned  
881 using MAFFT<sup>49</sup>. For viral species with fewer than 1000 sequences, MAFFT's 'FFT-NS-  
882 ix1000' algorithm was used. For viral species with >1000 sequences, MAFFT's 'FFT-  
883 NS-1' algorithm was used. These aligned sequences were then fed into ADAPT for  
884 crRNA design with high coverage using the 'minimize guides' objective (>90% of  
885 sequences detected). Once highly conserved regions of the viral genome were selected  
886 with ADAPT for optimal guide design, primers were manually designed to amplify a 100-  
887 250 bp target region with the crRNA predicted to bind in the middle of the fragment.  
888 ADAPT's constraints on primer specificity were relaxed and in some cases multiple  
889 primers were needed to encompass the full genomic diversity of a particular virus  
890 species. For optimal amplification, the primers were split into two pools. These primer  
891 pools and crRNA sequences are listed in Supp. Table 2.

892

### 893 **3aii. Target control - PIC1 and PIC2**

894 The consensus sequences generated directly above after multiple genome alignment  
895 with MAFFT were used to order a 500 bp dsDNA fragment encompassing the primer  
896 and crRNA binding sites. RNA was generated following the method described in  
897 'General mCARMEN Procedure - Preparation of IVT Material' and diluted to  $10^6$   
898 copies/ $\mu$ l in pools based on the primer pools mentioned above (PIC1, PIC2). The PICs  
899 were used as input into the CARMEN v1 or mCARMEN detection reaction to function as  
900 a detection positive control.

901

902 **3b. Sample Extraction: Manual or Automated**

903 Automated and manual extraction was performed according to methods described  
904 under 'General mCARMEN Procedures - Extraction'

905  
906 **3c. Amplification: Two-Step**

907 We followed the CARMEN v1 platform for two-step reverse transcription amplification,  
908 which was performed first by cDNA synthesis and then by PCR.

909  
910 **3ci. cDNA synthesis using SSIV**

911 10  $\mu$ L of extracted RNA was converted into single-stranded cDNA in a 40  $\mu$ L reaction.  
912 First, Random Hexamer Primers (ThermoFisher) were annealed to sample RNA at  
913 70 °C for 7 min, followed by reverse transcription using SuperScript IV (Invitrogen) for  
914 20 min at 55 °C. cDNA was stored at -20 °C until use. DNase treatment was not  
915 performed at any point during sample preparation.

916  
917 **3cii. Q5 DNA amplification**

918 Nucleic acid amplification was performed via PCR using Q5 Hot Start polymerase  
919 (NEB) using primer pools (with 150 nM of each primer) in 20  $\mu$ L reactions. Amplified  
920 samples were added directly into the detection reaction or stored at -20 °C until use.  
921 The following thermal cycling conditions were used: (1) initial denaturation at 98 °C for 2  
922 min; (2) 45 cycles of 98 °C for 15 s, 50 °C for 30 s, and 72 °C for 30 s; (3) final extension  
923 at 72 °C for 2 min. Each target was amplified with its corresponding primer pool, as  
924 listed under 'oligonucleotides used in this study.'

925  
926 **3d. Detection**

927 **3di. CARMEN-Droplet**

928 For colour coding, unless specified otherwise, amplified samples were diluted 1:10 into  
929 nuclease-free water supplemented with 13.2 mM MgCl<sub>2</sub> prior to colour coding to  
930 achieve a final concentration of 6 mM after droplet merging. Detection mixes were not  
931 diluted. Colour code stocks (2  $\mu$ l) were arrayed in 96W plates (for detailed information  
932 on construction of colour codes, see 'Colour code design, construction and  
933 characterization'). Each amplified sample or detection mix (18  $\mu$ l) was added to a  
934 distinct colour code and mixed by pipetting.

935  
936 For emulsification, the colour-coded reagents (20  $\mu$ l) and 2% 008-fluorosurfactant (RAN  
937 Biotechnologies) in fluoros oil (3M 7500, 70  $\mu$ l) were added to a droplet generator  
938 cartridge (Bio Rad), and reagents were emulsified into droplets using a Bio Rad QX200  
939 droplet generator or a custom aluminum pressure manifold.

940  
941 For droplet pooling, a total droplet pool volume of 150  $\mu$ l of droplets was used to load  
942 each standard chip; a total of 800  $\mu$ l of droplets was used to load each mChip. To  
943 maximize the probability of forming productive droplet pairings (amplified sample droplet  
944 + detection reagent droplet), half the total droplet pool volume was devoted to target  
945 droplets and half to detection reagent droplets. For pooling, individual droplet mixes  
946 were arrayed in 96W plates. A multichannel pipette was used to transfer the requisite  
947 volumes of each droplet type into a single row of eight droplet pools, which were further

948 combined to make a single droplet pool. The final droplet pool was pipetted up and  
949 down gently to fully randomize the arrangement of the droplets in the pool. The pooling  
950 step is rapid (<10 min), and small molecule exchange between droplets during this  
951 period does not substantially alter the colour codes.

952

### 953 **3dii. mCARMEN**

954 We followed the methods under General CARMEN Procedures - Detection - Fluidigm  
955 detection with the following modifications: 42.5 nM LwaCas13 and 212.5 nM crRNA in  
956 each assay mix reaction, and 500 nM RNaseAlert v2 in each sample mix reaction.

957

## 958 **3e. Data Analysis**

### 959 **3ei. CARMEN v1**

960 We followed the data analysis pipeline from CARMEN v1 to demultiplex and readout the  
961 fluorescence intensity of the reporter channel for each droplet reaction performed (REF  
962 CARMEN v1). In brief, pre-merge imaging data was processed using custom Python  
963 scripts to detect fluorescently-encoded droplets in microwells and identify their inputs  
964 based on their fluorescence intensity in three encoding channels, 647 nm, 594 nm, and  
965 555 nm. Subsequently, post-merge imaging data was analyzed to extract the reporter  
966 signal of the assay in the 488 nm channel, and those reporter fluorescence intensities  
967 were physically mapped to the contents of each microwell. Quality control filtering was  
968 performed based on the appropriate size of a merged droplet from two input droplets  
969 and the closeness of a droplet's color code to its assigned color code cluster centroid.  
970 The median and standard error were extracted from the replicates of all assay  
971 combinations generated on the array.

972

### 973 **3eii. mCARMEN**

974 We followed the methods under 'General CARMEN Procedures - Fluidigm Data  
975 Analysis' and further visualized the data using python, R, and Prism.

976

## 977 **4. Single-step amplification troubleshooting.**

978 The following RT-PCR kits were tested to determine the best performing assay: (1)  
979 OneStep RT-PCR Kit (Qiagen) (2) TaqPath™ 1-Step Multiplex Master Mix (Thermo  
980 Fisher), (3) One Step PrimeScript™ RT-PCR Kit (Takara), (4) GoTaq® Probe RT-qPCR  
981 Kit (Promega), (5) UltraPlex™ 1-Step ToughMix® (4X) (Quantbio), (6) iTaq™ Universal  
982 One-Step Kits for RT-PCR (Bio-Rad). Of the kits tested, the OneStep RT-PCR Kit  
983 (Qiagen) was chosen for the final mCARMEN protocol.

984

### 985 **4a. OneStep RT-PCR Kit (Qiagen)**

986 All or a combination of the following thermal cycling condition ranges were tested to  
987 shorten assay run-time: reverse-transcription at 50 °C at 15-30 min, PCR activation at  
988 95 °C at 5-15 min, denaturation step at 94 °C at 10-30 s, and extension step at 72 °C for  
989 10 s to 1 min. The final extension at 72 °C for 10 min was omitted in all runs. The  
990 following primer pool conditions were also tested to optimize the assay: 150 nM, 300  
991 nM, 500 nM, and 600 nM of virus-specific primer and 100 nM and 150 nM of RNaseP  
992 primers, with 5 µM of each virus-specific primer and 1.7 µM of RNaseP primers.  
993 Reaction volumes tested include: 20 µl with 10% RNA template input, 30 µl with 20%

994 RNA template input, and 50 µl with 20% RNA template input. The final amplification  
995 conditions used for the RVP panel are described under ‘General mCARMEN  
996 Procedures - Amplification’.

997

#### 998 **4b. TaqPath™ 1-Step Multiplex Master Mix Kit (Thermo Fisher)**

999 The TaqPath™ 1-Step Multiplex Master Mix Kit (Thermo Fisher) was used to amplify  
1000 nucleic acid according to the manufacturer's instructions, using custom primer pools in  
1001 20 µl reactions. Primer pools of 150 nM, 300 nM, and 500 nM and anneal temperatures  
1002 of 58 °C and 60 °C and were all tested and compared to determine optimal conditions.  
1003 The following thermal cycling conditions were used: (1) UNG passive reference  
1004 incubation at 25 °C for 2 min; (2) reverse-transcription incubation at 50 °C for 15 min; (3)  
1005 enzyme activation at 95 °C for 2 min (4) 40 cycles of 95 °C for 3 s and 60 °C for 30 s.  
1006 Amplified samples were directly added into the detection reaction or stored at -20 °C  
1007 until use.

1008

#### 1009 **4c. GoTaq® Probe RT-qPCR Kit (Promega)**

1010 The GoTaq® Probe RT-qPCR Kit (Promega) was used to amplify nucleic acid via RT-  
1011 PCR according to the manufacturer's instructions, using custom primer pools in 20 µl  
1012 reactions. Primer pools of 200 nM, 300 nM, and 500 nM were tested and compared to  
1013 determine optimal conditions. Each target in the panel was amplified with its  
1014 corresponding primer pool. The following thermal cycling conditions were used: (1)  
1015 reverse-transcription at 45 °C for 15 min and 95 °C for 2 min; (2) 40 cycles of 95 °C for  
1016 15 s, 60 °C for 1 min. Amplified samples were directly added into the detection reaction  
1017 or stored at -20 °C until use.

1018

#### 1019 **4d. UltraPlex™ 1-Step ToughMix® (4X) (Quantbio)**

1020 The UltraPlex™ 1-Step ToughMix® (4X) (Quantbio) was used to amplify nucleic acid via  
1021 RT-PCR according to the manufacturer's instructions, using custom primer pools in 20  
1022 µl reactions. Primer pools of 200 nM, 300 nM, and 500 nM were tested and compared to  
1023 determine optimal conditions. Each target in the panel was amplified with its  
1024 corresponding primer pool. The following thermal cycling conditions were used: (1)  
1025 reverse-transcription at 50 °C for 10 min and 95 °C for 3 min; (2) 45 cycles of 95 °C for  
1026 10 s, 60 °C for 1 min. Amplified samples were directly added into the detection reaction  
1027 or stored at -20 °C until use.

1028

### 1029 **5. RVP Testing at Broad research laboratory (Fig. 2)**

#### 1030 **5a. Design of 9-virus respiratory panel and RNase P**

1031 We designed this panel according to the methods described above under ‘Respiratory  
1032 Panel - Design’ for these 9 viruses: SARS-CoV-2, HCoV-HKU1, HCoV-OC43, HCoV-  
1033 NL63, FLUAV, FLUAV-g4, FLUBV, HPIV-3, HRSV, and HMPV, with the addition of an  
1034 RNase P primer pair and crRNA. RNase P primers and crRNAs were designed within  
1035 the same region of the gene as the CDC RT-qPCR assay (Supp. Table 2).

1036

#### 1037 **5b. Patient Specimen Validation**

1038 All patient specimens evaluated on RVP were additionally evaluated concurrently with  
1039 the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel for N1 and RNase P. A  
1040 subset of specimens were selected for further study using Next Generation Sequencing.

1041  
1042 Of the 533 patient specimens evaluated only two specimens had no detectable levels of  
1043 RNase P above threshold, one of which was positive for SARS-CoV-2 while the other  
1044 was virus-negative. The RNase P negative, but virus-positive, specimen likely has a  
1045 high concentration of viral RNA, which sequesters amplification materials during the  
1046 reaction, limiting RNase P amplification. The double negative specimen suggests  
1047 possible extraction failure or sample integrity issues and was thus excluded from further  
1048 analysis.

#### 1049 1050 **5bi. RVP Detection**

1051 Specimen preparation was performed according to the method outlined in 'General  
1052 mCARMEN Procedures - Sample Extraction' with 200  $\mu$ L of input material. Amplification  
1053 was performed according to methods outlined in 'General mCARMEN Procedures -  
1054 Amplification' Detection reactions were prepared as described in 'General mCARMEN  
1055 Procedures - Detection' with the following modifications: 42.5 nM LwaCas13 and 212.5  
1056 nM crRNA in each assay mix reaction, and 500 nM quenched synthetic fluorescent RNA  
1057 reporter (FAM/rUrUrUrUrUrUrU/3IABkFQ/) in each sample mix reaction. Results were  
1058 analyzed following methods outlined under 'General mCARMEN Procedures - Data  
1059 Analysis'.

#### 1060 1061 **5bii. CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel - Research Use Only**

1062 The CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel was performed using  
1063 TaqPath 1-Step RT-qPCR Master Mix (Thermo Fisher) with 1  $\mu$ L template RNA of either  
1064 SARS-CoV-2 or RNase P in 10  $\mu$ L reactions, run in triplicate. Primers from the [2019-  
1065 nCoV RUO Kit](#) (IDT) were used. For SARS-CoV-2 a primer pool at 800  $\mu$ M and probe at  
1066 200  $\mu$ M was used. For RNaseP, a primer pool at 500  $\mu$ M and a probe at 125  $\mu$ M was  
1067 used. The following thermal cycling conditions were used: (1) enzyme activation at  
1068 25  $^{\circ}$ C for 2 min; (2) reverse-transcription at 50  $^{\circ}$ C for 15 min; (3) PCR activation at 95  $^{\circ}$ C  
1069 for 2 min; (4) 45 cycles of 95  $^{\circ}$ C for 3 s and 55  $^{\circ}$ C for 30 s. Standard curves were made  
1070 with spike-in of RNA template (SARS-CoV-2 and RNaseP) to make a ten-fold serial  
1071 dilution from  $10^0$  to  $10^6$  copies/ $\mu$ L. This was run on the QuantStudio™  
1072 6 Flex System.

#### 1073 1074 **5eiii. Next Generation Sequencing**

1075 Metagenomic sequencing libraries were generated as previously described<sup>6,50</sup>. Briefly,  
1076 extracted RNA was DNase treated to remove residual DNA then human rRNA was  
1077 depleted. cDNA was synthesized using random hexamer primers. Sequencing libraries  
1078 were prepared with Illumina Nextera XT DNA library kit and sequence with 100-  
1079 nucleotide or 150-nucleotide paired-end reads. Data analysis was conducted on the  
1080 Terra platform (app.terra.bio); all workflows are publicly available on the Dockstore Tool  
1081 Registry Service. Samples were demultiplexed using demux\_plus to filter out known  
1082 sequencing contaminants. SARS-CoV-2 genomes were assembled using  
1083 assemble\_refbased, all other viral genomes were assemble\_denovo and additionally

1084 visualized using classify\_kraken, geneious, and R. A virus was determined to be  
1085 present if more than 10 reads mapped to a particular viral genome. Full genomes were  
1086 deposited into GenBank (Accession # here).

1087

## 1088 **6. Clinical Evaluation of RVP in CLIA-certified laboratory at MGH (Fig. 3)**

### 1089 **6a.RVP preparation**

1090

#### 1091 **6ai. Design**

1092 We designed this panel according to the methods described above under 'RVP Testing  
1093 at Broad - Design'.

1094

#### 1095 **6aii. Controls**

1096 *Automated Extraction, KingFisher Control: Extraction Negative Control (EC)* is an RNA  
1097 extraction control and is prepared by adding 200  $\mu$ L pooled human sample (negative for  
1098 all viruses on the panel) to a well with 280  $\mu$ L of binding bead mix (preparation  
1099 described in 'Automated Extraction, KingFisher'). The EC should yield a positive result  
1100 for the RNaseP crRNA and primer pair and a negative result for all other targets.

1101

1102 *Nucleic acid amplification controls: No Template Control (NTC)* is a negative control for  
1103 nucleic acid amplification and is prepared by adding 10  $\mu$ L nuclease-free water (instead  
1104 of RNA) into 40  $\mu$ L of OneStep RT-PCR Kit (Qiagen) mastermix. This should yield a  
1105 negative result for all targets on the panel. *Combined Positive Control (CPC)* is a  
1106 positive control for nucleic acid amplification and is prepared by pooling *in vitro*  
1107 transcribed synthetic RNA of all the targets on the panel to  $10^3$  copy/ $\mu$ L. 11  $\mu$ L aliquots of  
1108 this mix are stored at  $-80^{\circ}\text{C}$  until use, when 10  $\mu$ L are added to 40  $\mu$ L of OneStep RT-  
1109 PCR Kit (Qiagen) mastermix. This should yield a positive result for all targets on the  
1110 panel.

1111

1112 *Cas13-Detection Controls: Negative Detection Control (NDC)* is a negative control for  
1113 the Fluidigm-detection step and is prepared by adding nuclease-free water (instead of  
1114 amplified RNA) to the sample mix without  $\text{MgCl}_2$ . This should yield a negative result for  
1115 all targets on the panel. *No crRNA control (no-crRNA)* is a negative control for the  
1116 Fluidigm-detection step and is prepared by adding nuclease-free water (instead of 1  $\mu$ M  
1117 crRNA) to the assay mix. This should yield a negative result for all targets on the panel.

1118

#### 1119 **6aiii. Batch preparation of sample and assay mixtures**

1120 Sample and assay mixtures can be prepared in advance for multiple 96-sample batches  
1121 following similar methods, with the following changes: the batch sample mix contained  
1122 all reagents described above, excluding 9 mM  $\text{MgCl}_2$ , and the batch assay mix  
1123 contained all reagents described above, excluding 2x Assay Loading Reagent. Both  
1124 mixtures were calculated with 10% overage. Both mixtures were stored at  $-80^{\circ}\text{C}$  until  
1125 use. 9 mM  $\text{MgCl}_2$  was added to the sample mix and 2x Assay Loading Reagent was  
1126 added to each assay mix before use.

1127

#### 1128 **6aiv. SYBR RT-qPCR of viral seed stock and genomic RNA from ATCC and BEI** 1129 **Resources**

1130 Quantification of all viral seed stock and genomic RNA received from ATCC and BEI  
1131 resources was performed using the Power SYBR Green RNA-to-Ct 1-Step Kit  
1132 (ThermoFisher). Reactions were run in triplicate with 1  $\mu$ L RNA input in 10  $\mu$ L reactions.  
1133 A primer mix at 500nM was used, and all primer sequences used are listed in Supp.  
1134 Table 2. The following thermal cycling conditions were used: (1) reverse transcription at  
1135 48 °C for 30 min; (2) enzyme activation at 95 °C for 10 min; (3) 40 cycles of 95 °C for 15  
1136 s and 60 °C for 1 min; (4) melt curve of 95 °C for 15 s, 60 °C for 15 s, and 95 °C for 15 s.  
1137 Standard curves were made with spike-in of RNA template to make a ten-fold serial  
1138 dilution from  $10^0$  to  $10^6$  copies/ $\mu$ L. This was run on the QuantStudio™ 6 Flex System.  
1139

### 1140 **6b. Limit of Detection (LOD)**

1141 Samples were prepared for the LOD experiments using either quantified viral isolates,  
1142 genomic RNA or IVT partial gene fragments. For the SARS-CoV-2, HCoV-OC43,  
1143 HRSV, and HPIV-3 assays, quantified viral isolates of known titer (RNA copies/ $\mu$ L)  
1144 spiked into pooled negative human sample (negative for all viruses on the panel) in  
1145 Universal Transport Media (UTM), to mimic clinical specimen. The pooled human  
1146 negative samples were incubated in the binding bead mix solution according to the  
1147 methods described in 'General mCARMEN Procedures - Extraction - Automated.' Since  
1148 no quantified virus isolates for HCoV-NL63, HCoV-HKU-1, FLUAV, FLUAV-g4, FLUBV,  
1149 and HMPV were available for use at the time the study was conducted, assays  
1150 designed for RNA detection of these viruses were tested with either genomic RNA from  
1151 ATCC (FLUAV: cat# NR-43756; FLUBV: cat# VR-1804) or IVT RNA of known titer were  
1152 spiked into pooled negative human samples in UTM.  
1153

1154 RNA was extracted from 200  $\mu$ L of input material using the MagMAX™ DNA Multi-  
1155 Sample Ultra 2.0 Kit on a KingFisher™ Flex Magnetic Particle Processor with 96 Deep-  
1156 Well Head (Thermo Fisher Scientific). This was run according to the protocol listed in  
1157 [TaqPath™ COVID-19 Combo Kit Protocol](#) under "KingFisher, "Extract RNA - Automated  
1158 method (200  $\mu$ L input volume)" with the following differences: To prepare the binding  
1159 bead mix, the following was added: 265  $\mu$ L binding solution, 10  $\mu$ L total nucleic acid  
1160 magnetic beads, 5  $\mu$ L Proteinase K with 10% overage for multiple samples. 280  $\mu$ L of  
1161 the binding bead mix was added to each sample well. The 200  $\mu$ L of input material  
1162 includes negative human sample and RNA: 160  $\mu$ L of pooled human samples (negative  
1163 for all viruses on the panel) was added to each sample well and incubated for 20  
1164 minutes before 40  $\mu$ L of RNA was spiked in. Samples were eluted in 50  $\mu$ L of elution  
1165 solution and either directly added to the amplification reaction or stored at -80 °C until  
1166 use.  
1167

1168 A preliminary LOD for each assay was determined by testing triplicates of RNA purified  
1169 using the extraction method described in 'RVP panel'. The approximate LOD was  
1170 identified by extraction, amplification, and detection of 10-fold serial dilutions of IVT  
1171 RNA of known titer (copies/ $\mu$ L) for 5 replicates. These concentrations ranged from  $1e4$ -  
1172  $1e-3$  copies/ $\mu$ L. The lower bound of the LOD range was determined as the lowest  
1173 concentration where 5/5 replicates were positive, and the upper bound was determined  
1174 as the concentration 10-fold above the lower bound. A confirmation of the LOD for each  
1175 assay was determined by testing 20 replicates of RNA, purified using the extraction

1176 method described in 'RVP panel'. The approximate LOD was identified by extraction,  
1177 amplification, and detection of 2-fold serial dilutions of the input sample, quantified viral  
1178 isolates, genomic RNA or IVT RNA. These concentrations ranged from 20-0.5  
1179 copies/ $\mu$ L, depending on the virus. The LOD was determined as the lowest  
1180 concentration where  $\geq 95\%$  (19/20) of the replicates were positive.

1181

## 1182 **6c. Specificity**

### 1183 **Design of targets for specificity.**

#### 1184 *In silico analysis - Inclusivity*

1185 Inclusivity was tested by performing an *in silico* analysis using all publicly available  
1186 sequences of all targets on the RVP panel. Complete genomes for all viruses were  
1187 downloaded from NCBI on April 2, 2021 and aligned using MAFFT v7. For viral species  
1188 with less than 1000 sequences, the FFT-NS-ix1000 algorithm was used to create the  
1189 MAFFT alignment. For viral species with >1000 sequences, the FFT-NS-1 algorithm  
1190 was used to create the MAFFT alignment. The primer and crRNA sequences were then  
1191 mapped to the aligned viral sequences using a consensus alignment to determine the  
1192 percent identity (homology) and the number of mismatches. The average homology and  
1193 mismatches were taken across the total number of sequences evaluated. Please note  
1194 that mismatches below for crRNA sequences do not take wobble base pairing (G-U  
1195 pairing) into account. Results are summarized in Supp. Table 5.

1196

1197 Additionally the SARS-CoV-2 crRNA and primer sequences were tested by NCBI  
1198 BLAST+ against the nr/nt databases (updated 03/31/2021, N=68965867 sequences  
1199 analyzed) and the Betacoronavirus database (updated 04/01/2021, N=140760). The  
1200 search parameters were adjusted to blastn-short for short input sequences. The match  
1201 and mismatch scores are 1 and -3, respectively. The penalty to create and extend a gap  
1202 in an alignment is 5 and 2, respectively. Blast results confirmed only perfect matches to  
1203 SARS-CoV-2.

1204

#### 1205 *In silico analysis - Specificity*

1206 Complete genomes for all viruses were downloaded from NCBI on April 2, 2021 and  
1207 aligned using MAFFT. For viral species with less than 1000 sequences, FFT-NS-ix1000  
1208 was used. For viral species with >1000 sequences, FFT-NS-1 was used for the MAFFT  
1209 alignment. The primer and crRNA sequences were then mapped to the aligned viral  
1210 sequences using a consensus alignment to determine percent identity (homology). The  
1211 average homology was taken across the panel sequences and the total number of  
1212 sequences evaluated. Bolded text represents on-target primers/crRNA to the intended  
1213 viral sequences. Not all sequence combinations were evaluated since whole genome  
1214 homology between many viruses is significantly less than 80%. All primer and crRNA  
1215 sequences do not have >80% homology to other, unintended viral or bacterial  
1216 sequences, making the panel highly specific to particular viruses of interest. More  
1217 specifically, no *in silico* cross-reactivity >80% homology between any primers and  
1218 crRNA sequences on RVP is observed for the following common respiratory flora and  
1219 other viral pathogens: SARS-CoV-1, HCoV-MERS, Adenovirus, Enterovirus, Rhinovirus,  
1220 *Chlamydia pneumoniae*, *Haemophilus influenzae*, *Legionella pneumophila*,  
1221 *Mycobacterium tuberculosis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*,



1222 *Bordetella pertussis*, *Mycoplasma pneumoniae*, *Pneumocystis jirovecii*, *Candida*  
1223 *albicans*, *Pseudomonas aeruginosa*, *Staphylococcus epidermis*, *Streptococcus*  
1224 *salivarius*. In silico analysis results are summarized in Supp. Table 6.

1225

#### 1226 *In vitro* analysis

1227 Samples were prepared for specificity experiments according to methods described  
1228 above in 'General mCARMEN Procedures - Preparation of IVT material', and samples  
1229 were serially diluted down to a concentration of  $10^6$  and  $10^5$  copies/ $\mu$ L. For all samples  
1230 prepared for specificity experiments, RNA was extracted from 200  $\mu$ L of input material  
1231 using the MagMAX™ DNA Multi-Sample Ultra 2.0 Kit on a KingFisher™ Flex Magnetic  
1232 Particle Processor. This was run according to the extraction, amplification, and  
1233 detection methods described above under 'RVP Testing at Broad.'

1234

### 1235 **6d. Patient Specimen Validation**

#### 1236 **6di. Specimen preparation prior to extraction**

1237 All patient specimens from the MGH Clinical Microbiology Lab were initially reported to  
1238 be positive for HCoV-HKU1, HCoV-NL63, and HMPV via BioFire FilmArray Respiratory  
1239 Panel (RP2) or positive for SARS-CoV-2, FLUAV (H3), FLUBV, and HRSV via  
1240 [Xpert® Xpress SARS-CoV-2/Flu/RSV \(Cepheid\)](#). 200  $\mu$ L of positive for SARS-CoV-2  
1241 were aliquoted as follows: 220  $\mu$ L for testing using the RVP panel, 220  $\mu$ L for testing  
1242 using the TaqPath™ COVID-19 Combo Kit, and all remaining specimens were stored at  
1243  $-80$  °C. All negative specimens were aliquoted: 220  $\mu$ L for RVP panel testing, 220  $\mu$ L  
1244 for TaqPath™ COVID-19 Combo Kit testing, 400  $\mu$ L for BioFire FilmArray Respiratory  
1245 Panel (RP2) testing, and all remaining specimen was stored at  $-80$  °C. All other  
1246 specimens were aliquoted: 220  $\mu$ L for RVP panel testing, 400  $\mu$ L for BioFire FilmArray  
1247 Respiratory Panel (RP2) testing, and all remaining specimen was stored at  $-80$  °C.

1248

#### 1249 **6dii. Preparation of contrived samples prior to extraction**

1250 Contrived patient samples of viruses HCoV-HKU1, HCoV-OC43, HCoV-NL63, FLUAV-  
1251 g4, HPIV-3, and HMPV were prepared by diluting either viral seed stock (HCoV-OC43  
1252 and HPIV-3) or template RNA (HCoV-HKU1 and HCoV-NL63). See Supp. Table 7 for  
1253 viral seed stock vendor details. The viral seed stock or template RNA is added to non-  
1254 pooled human specimens (negative for all targets, except RNase P, on the RVP panel)  
1255 at a concentration 2 times the LOD; the concentrations for these samples ranged from  
1256  $10^2$  to  $10^6$  copies/ $\mu$ L.

1257

#### 1258 **6diii. RVP**

1259 All materials were extracted, amplified, detected, and analyzed using methods  
1260 described under 'General mCARMEN Procedures' and 'RVP Testing at Broad - Patient  
1261 Specimen Validation.'

1262

#### 1263 **6div. TaqPath™ COVID-19 Combo Kit**

1264 A subset of patient specimens, all SARS-CoV-2 and negative patient specimens, from  
1265 the MGH Clinical Microbiology Laboratory were verified using the TaqPath™ COVID-19  
1266 Combo Kit (ThermoFisher). These samples were initially reported to be positive for  
1267 SARS-CoV-2 via Xpert® Xpress SARS-CoV-2/Flu/RSV (Cepheid) or reported to be

1268 negative for all targets (excluding RNaseP) on the RVP panel via BioFire FilmArray  
1269 Respiratory Panel (RP2).The TaqPath™ COVID-19 Combo Kit was performed  
1270 according to the manufacturer's instructions. The assay was performed using the  
1271 Applied Biosystems 7500.

1272

### 1273 **6dv. BioFire FilmArray Respiratory Panel (RP2)**

1274 A subset of patient specimens from the MGH Clinical Microbiology Laboratory, all  
1275 HCoV-HKU1, HCoV-NL63, FLUAV (H3), FLUBV, HRSV, HMPV and negative patient  
1276 specimens, were verified using the BioFire FilmArray Respiratory Panel (RP2) (Biofire  
1277 Diagnostics). These specimens were either initially reported to be positive for HCoV-  
1278 HKU1, HCoV-NL63, and HMPV via BioFire FilmArray Respiratory Panel (RP2) or  
1279 positive for FLUAV (H3), FLUBV, and HRSV via [Xpert® Xpress Flu/RSV \(Cepheid\)](#). For  
1280 each run, one patient specimens in UTM at 300 µL was verified using the BioFire  
1281 FilmArray Respiratory Panel (RP2) according to the [manufacturer's instructions](#). Any  
1282 remaining specimen was stored at -80°C.

1283

1284 Controls for this assay were received with the kit and ready for use. Control 1 is  
1285 expected to be positive for adenovirus, HMPV, Human Rhino/Enterovirus, FLUAV (H1-  
1286 2009), FLUAV (H3), HPIV-1, HPIV-2. Control 2 is expected to be positive for HCoV-  
1287 229E, HCoV-HKU1, HCoV-NL63, HCoV-OC43, FLUAV (H1), FLUBV, HPIV-2, HPIV-3,  
1288 HRSV.

1289

1290 The results were automatically displayed on the FilmArray software with each target in a  
1291 run reported as “detected” or “not detected.” If either control fails, the software marks  
1292 this run as “invalid.” When sufficient human sample volume was available, samples with  
1293 invalid results were re-run.

1294

### 1295 **6e. Analysis Software**

1296 The analysis software comprises python scripts executing the data analysis described in  
1297 Methods 2h and taking into account the controls described in Methods section 6aii.  
1298 They are packaged into an executable with graphical user-interface using the Python  
1299 module Goey 1.0.7.

1300

1301 In short, the reference-normalized background-subtracted fluorescence is calculated for  
1302 guide-target pairs for the measurement after 60 min. Then, the dynamic range and the  
1303 separation band are assessed.

1304

1305 Separation band = (mean of positive controls - 3 standard deviations of positive  
1306 controls) - (mean of negative controls - 3 standard deviations of negative controls)  
1307 Dynamic range = | mean of positive controls - mean of negative controls|

1308

1309 If the ratio of separation band to dynamic range is equal or less than 0.2, the whole assay  
1310 is invalid. Next, for the positive and negative controls, outliers based on three standard  
1311 deviations are identified. If a positive control has a too low value or a negative control a  
1312 too high value, the respective assay is invalid. For the remaining samples, hit calling is  
1313 performed based on comparing the signal to the water control. If the signal is 1.8x

1314 higher than the water control, the guide-target pair is called a hit. Based on this hit  
1315 calling, the extraction control, the negative and positive detection controls and internal  
1316 controls are verified. If their result does not correspond to their expected hit status,  
1317 either the respective assay or specimens is turned invalid. All patients specimens to be  
1318 valid need to be either positive for RNase P or at least one other assay. Finally, the  
1319 software annotates the results as csv files and visualizes them as an annotated  
1320 heatmap.

1321

## 1322 **7. Variant Testing (Fig. 4)**

### 1323 **7a. Design**

1324 The crRNAs for SNP discrimination were designed using a generative sequence design  
1325 algorithm (manuscript in prep.). This approach uses ADAPT's predictive model to  
1326 predict the activity of candidate crRNA sequences against on-target and off-target  
1327 sequences<sup>35</sup>. These predictions of candidate crRNA activity steer the generative  
1328 algorithm's optimization process, in which it seeks to design crRNA probes that have  
1329 maximal predicted on-target activity and minimal predicted off-target activity. Using this  
1330 design algorithm, we selected the 26 mutations to detect and discriminate between the  
1331 variants (Supp. Table 2).

1332

### 1333 **7b. Amplification**

1334 We followed the methods under 'General mCARMEN Procedures - Amplification -  
1335 SSIV,' sequences of primers used can be found in Supp. Table 2.

1336

### 1337 **7c. Detection**

1338 We followed the methods under 'General mCARMEN Procedures - Detection' with the  
1339 following modifications: 42.5 nM LwaCas13 and 2-212.5 nM crRNA in each assay mix  
1340 reaction, and 500 nM RNaseAlert v2 in each sample mix reaction. Exact crRNA  
1341 concentrations can be found in Supp. Table 2.

1342

### 1343 **7d. Data analysis**

1344 Threshold calculation:

1345 To determine if an ancestral or derived sequence is present, the signals between  
1346 respective ancestral and derived crRNA pairs must be evaluated and compared (Supp.  
1347 Table 2). First, background subtracted reporter fluorescence is normalized to the  
1348 background subtracted passive reference dye (ROX) fluorescence for each assay in the  
1349 IFC. Next, the ancestral:derived and derived:ancestral ratios are calculated for each five  
1350 minute-interval time point across 180 minutes. For each crRNA pair, the ratio reaching a  
1351 crRNA pair-specific threshold at the earliest time point is selected. If the  
1352 ancestral:derived ratio is selected, then the sequence present is determined to be  
1353 ancestral. If the derived:ancestral ratio is selected, then the sequence present is  
1354 determined to contain the mutation targeted by the derived crRNA within the SARS-  
1355 CoV-2 spike gene. crRNA pair-specific thresholds were determined based on ancestral  
1356 and variant control samples, also referred to as the seedstock samples, tested in  
1357 parallel with the unknown samples. For a given crRNA pair, the threshold was set to the  
1358 lowest value with the maximum combined sensitivity and specificity when applied to the  
1359 seedstock samples. For crRNA's detecting a SNP at the same position, the second

1360 lowest threshold with the maximum combined sensitivity and specificity was chosen if  
1361 possible without compromising the maximum combined sensitivity and specificity. For  
1362 crRNA pairs targeting mutations not represented in the variant control samples, a  
1363 default crRNA pair threshold of 1.5 was set. Expected mutations for each variant  
1364 lineage:

1365  
1366

**Table 1. Expected mutations for each SARS-CoV-2 variant lineage.**

Alpha (B.1.1.7)	Beta (1.1.351)	Gamma (P.1)	Delta (B.1.617.2)	Epsilon (B.1.1.427/9)
Δ69/70	L18F	L18F	L452R	S13I
N501Y	D80A	P26S	T478K	P26S
A570D	K417N	K417T	D614G	L452R
D614G	E484K	E484K	P681R	D614G
P681H	N501Y	N501Y		
	D614G	D614G		
		H655Y		

1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379

“Variant Identified” hit calling parameters:

- 1) If no mutations are detected, a result of “Ancestral” is returned.
- 2) At least one unique crRNA specific to a single SARS-CoV-2 variant must be above the fluorescence ratio threshold. If there is not one unique crRNA signal above threshold, a result of “Variant Not Identified” will be returned.
- 3) If two or more mutations for a given variant fall below the threshold, a result of “Variant Not Identified” will be returned. All other mutations must surpass the threshold.
- 4) If three or more unexpected mutations for a given variant are above threshold, a result of “Variant Not Identified” will be returned. At most, two unexpected signals can occur as long as parameters 1 and 2 are met.

1380 If all three parameters are met, the result of “Variant Identified” will be returned. If the  
1381 parameters are not met, a result of “Variant Not Identified” will be returned. Samples  
1382 that contain additional derived signals that fall outside of the typical variant lineage  
1383 mutation list follow the below parameters. If 1-2 unexpected signals are observed  
1384 slightly above threshold yet all other signals are correct for a specific variant lineage  
1385 then the unexpected signal will be disregarded and the variant call will be made on the  
1386 remaining signals. If more than two unexpected signals are observed above threshold  
1387 and either all other signals are correct for a specific variant lineage or are not perfectly  
1388 matching a result of “Variant Uncertain” will be returned.  
1389

1390 \*We would like to note that the variant identification pipeline will need to be updated as  
1391 new SARS-CoV-2 mutations and variant lineages arise for proper identification.

1392  
1393 There are a few exceptions worth mentioning: we observed crRNAs for SNPs E484Q,  
1394 P681R, N501T, and L452Q, had undesirable cross-reactive signals with a position  
1395 matched or adjacent mutation, and were, thus, excluded from further evaluation.

## 1396 1397 **8. Cas13- and Cas12-based detection with mCARMEN (Fig. 5)**

### 1398 **8a. Design for Cas12-based detection**

1399 Cas13 crRNAs from RVP were utilized. Cas12 crRNAs were manually designed in the  
1400 same region of the viral genome as the Cas13 crRNAs to reduce the need for additional  
1401 primer design while maintaining Cas12's PAM requirements. Only one additional primer  
1402 was designed in order to properly amplify all targets on RVP. All crRNAs and primers are  
1403 listed in Supp. Table 2.

### 1404 1405 **8b. Detection**

1406 We followed the methods under 'General mCARMEN Procedures - Detection' with the  
1407 following modifications: 10-60 nM LwaCas13, 10-60 nM LbaCas12a, 125 nM Cas13a  
1408 crRNA, and 125 nM Cas12 crRNA in each assay mix reaction, and 500 nM quenched  
1409 synthetic fluorescent RNA reporter (FAM/rUrUrUrUrUrU/3IABkFQ/ and  
1410 VIC/rTrTrArTrTrArTrT/3IABkFQ) in each sample mix reaction.

### 1411 1412 **8c. Data analysis**

1413 We generally followed the methods under 'General mCARMEN Procedures - Analysis'  
1414 this time with also taking into account VIC signal separate from FAM signal. We used a  
1415 custom python script to determine whether the FAM signal of a reaction is significantly  
1416 above background by comparing it to the no-template control. If the background-  
1417 subtracted and normalized fluorescence intensity is 1.8 higher than the normalized and  
1418 background-subtracted no-templated control, the assay is considered positive.

## 1419 1420 1421 1422 **Citations**

- 1423 1. Mina, M. J. & Andersen, K. G. COVID-19 testing: One size does not fit all. *Science*  
1424 vol. 371 126–127 (2021).
- 1425 2. Rasmussen, A. L. & Popescu, S. V. SARS-CoV-2 transmission without symptoms.  
1426 *Science* **371**, 1206–1207 (2021).
- 1427 3. CDC. Labs. [https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)  
1428 [probes.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html) (2021).
- 1429 4. Winichakoon, P. *et al.* Negative Nasopharyngeal and Oropharyngeal Swabs Do Not  
1430 Rule Out COVID-19. *J. Clin. Microbiol.* **58**, (2020).
- 1431 5. Woloshin, S., Patel, N. & Kesselheim, A. S. False Negative Tests for SARS-CoV-2  
1432 Infection - Challenges and Implications. *N. Engl. J. Med.* **383**, e38 (2020).
- 1433 6. Lemieux, J. E. *et al.* Phylogenetic analysis of SARS-CoV-2 in Boston highlights the  
1434 impact of superspreading events. *Science* **371**, (2021).
- 1435 7. Harvey, W. T. *et al.* SARS-CoV-2 variants, spike mutations and immune escape.

- 1436 *Nature Reviews Microbiology* vol. 19 409–424 (2021).
- 1437 8. Tracking SARS-CoV-2 variants. [https://www.who.int/activities/tracking-SARS-CoV-](https://www.who.int/activities/tracking-SARS-CoV-2-variants)
- 1438 2-variants.
- 1439 9. Zou, L. *et al.* SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected
- 1440 Patients. *N. Engl. J. Med.* **382**, 1177–1179 (2020).
- 1441 10. Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019.
- 1442 *Nature* **581**, 465–469 (2020).
- 1443 11. Vogels, C. B. F. *et al.* Multiplex qPCR discriminates variants of concern to enhance
- 1444 global surveillance of SARS-CoV-2. *PLoS Biol.* **19**, e3001236 (2021).
- 1445 12. Heggstad, J. T. *et al.* Multiplexed, quantitative serological profiling of COVID-19
- 1446 from blood by a point-of-care test. *Sci Adv* **7**, (2021).
- 1447 13. Pham, J. *et al.* Performance Characteristics of a High-Throughput Automated
- 1448 Transcription-Mediated Amplification Test for SARS-CoV-2 Detection. *J. Clin.*
- 1449 *Microbiol.* **58**, (2020).
- 1450 14. TaqPath™ COVID-19 Combo Kit.
- 1451 <https://www.thermofisher.com/order/catalog/product/A47814>.
- 1452 15. CDC. CDC’s Influenza SARS-CoV-2 Multiplex Assay and Required Supplies.
- 1453 <https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html> (2021).
- 1454 16. Cepheid. Xpert Xpress SARS-CoV-2/Flu/RSV. [www.fda.gov](http://www.fda.gov)
- 1455 <https://www.fda.gov/media/142434/download> (2020).
- 1456 17. Eckbo, E. J. *et al.* Evaluation of the BioFire® COVID-19 test and Respiratory Panel
- 1457 2.1 for rapid identification of SARS-CoV-2 in nasopharyngeal swab samples. *Diagn.*
- 1458 *Microbiol. Infect. Dis.* **99**, 115260 (2021).
- 1459 18. ChromaCode. SARS-CoV-2 Assay Test from ChromaCode.
- 1460 <https://chromacode.com/products/hdpcr-sars-cov-2-assay/> (2020).
- 1461 19. Jacky, L. *et al.* Robust Multichannel Encoding for Highly Multiplexed Quantitative
- 1462 PCR. *Anal. Chem.* **93**, 4208–4216 (2021).
- 1463 20. Konings, F. *et al.* SARS-CoV-2 Variants of Interest and Concern naming scheme
- 1464 conducive for global discourse. *Nat Microbiol* **6**, 821–823 (2021).
- 1465 21. Center for Devices & Radiological Health. In Vitro Diagnostics EUAs - Molecular
- 1466 Diagnostic Tests for SARS-CoV-2. [https://www.fda.gov/medical-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2)
- 1467 [devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2)
- 1468 [medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2)
- 1469 (2021).
- 1470 22. Burki, T. Understanding variants of SARS-CoV-2. *Lancet* **397**, 462 (2021).
- 1471 23. Borges, V. *et al.* Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from
- 1472 nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL)
- 1473 data, Portugal, week 49 2020 to week 3 2021. *Euro Surveill.* **26**, (2021).
- 1474 24. Xuan, J., Yu, Y., Qing, T., Guo, L. & Shi, L. Next-generation sequencing in the
- 1475 clinic: promises and challenges. *Cancer Lett.* **340**, 284–295 (2013).
- 1476 25. Houldcroft, C. J., Beale, M. A. & Breuer, J. Clinical and biological insights from viral
- 1477 genome sequencing. *Nat. Rev. Microbiol.* **15**, 183–192 (2017).
- 1478 26. Peddu, V. *et al.* Metagenomic Analysis Reveals Clinical SARS-CoV-2 Infection and
- 1479 Bacterial or Viral Superinfection and Colonization. *Clin. Chem.* **66**, 966–972 (2020).
- 1480 27. Brito, A. F. *et al.* Global disparities in SARS-CoV-2 genomic surveillance. *medRxiv*
- 1481 (2021) doi:10.1101/2021.08.21.21262393.


- 1482 28. Abudayyeh, O. O. *et al.* C2c2 is a single-component programmable RNA-guided  
1483 RNA-targeting CRISPR effector. *Science* **353**, aaf5573 (2016).
- 1484 29. Gootenberg, J. S. *et al.* Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science*  
1485 **356**, 438–442 (2017).
- 1486 30. Jiao, C. *et al.* Noncanonical crRNAs derived from host transcripts enable  
1487 multiplexable RNA detection by Cas9. *Science* **372**, 941–948 (2021).
- 1488 31. Myhrvold, C. *et al.* Field-deployable viral diagnostics using CRISPR-Cas13. *Science*  
1489 **360**, 444–448 (2018).
- 1490 32. Chen, J. S. *et al.* CRISPR-Cas12a target binding unleashes indiscriminate single-  
1491 stranded DNase activity. *Science* **360**, 436–439 (2018).
- 1492 33. Li, S.-Y. *et al.* CRISPR-Cas12a-assisted nucleic acid detection. *Cell Discov* **4**, 20  
1493 (2018).
- 1494 34. Arizti-Sanz, J. *et al.* Streamlined inactivation, amplification, and Cas13-based  
1495 detection of SARS-CoV-2. *Nat. Commun.* **11**, 5921 (2020).
- 1496 35. Metsky, H. C. *et al.* Designing viral diagnostics with model-based optimization.  
1497 *bioRxiv* 2020.11.28.401877 (2021) doi:10.1101/2020.11.28.401877.
- 1498 36. Joung, J. *et al.* Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing. *N.*  
1499 *Engl. J. Med.* **383**, 1492–1494 (2020).
- 1500 37. Ackerman, C. M. *et al.* Massively multiplexed nucleic acid detection with Cas13.  
1501 *Nature* **582**, 277–282 (2020).
- 1502 38. Fluidigm. <https://www.fluidigm.com/products/biomark-hd-system>.
- 1503 39. Crowe, J. E. Human Respiratory Viruses☆. *Reference Module in Biomedical*  
1504 *Sciences* (2014) doi:10.1016/b978-0-12-801238-3.02600-3.
- 1505 40. TaqPath™ COVID-19 Combo Kit.  
1506 <https://www.thermofisher.com/order/catalog/product/A47814>.
- 1507 41. García Fernández, X., Álvarez-Argüelles, M. E., Rojo, S. & de-Oña, M. Stability of  
1508 viral RNA in clinical specimens for viral diagnosis. *Enferm. Infecc. Microbiol. Clin.*  
1509 **38**, 297–298 (2020).
- 1510 42. Palmenberg, A. C. *et al.* Sequencing and analyses of all known human rhinovirus  
1511 genomes reveal structure and evolution. *Science* **324**, 55–59 (2009).
- 1512 43. Office of the Commissioner. Emergency Use Authorization.  
1513 [https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization)  
1514 [and-policy-framework/emergency-use-authorization](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) (2021).
- 1515 44. Mackay, I. M., Arden, K. E. & Nitsche, A. Real-time PCR in virology. *Nucleic Acids*  
1516 *Res.* **30**, 1292–1305 (2002).
- 1517 45. Kirkland, P. D. & Frost, M. J. The impact of viral transport media on PCR assay  
1518 results for the detection of nucleic acid from SARS-CoV-2. *Pathology* **52**, 811–814  
1519 (2020).
- 1520 46. Fozouni, P. *et al.* Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a  
1521 and mobile phone microscopy. *Cell* **184**, 323–333.e9 (2021).
- 1522 47. Nalefski, E. A. *et al.* Kinetic analysis of Cas12a and Cas13a RNA-Guided nucleases  
1523 for development of improved CRISPR-Based diagnostics. *iScience* **24**, 102996  
1524 (2021).
- 1525 48. Thakku, S. G. *et al.* Multiplexed detection of bacterial nucleic acids using Cas13 in  
1526 droplet microarrays. *bioRxiv* 2021.11.12.468388 (2021)  
1527 doi:10.1101/2021.11.12.468388.

- 1528 49. Katoh, K. & Standley, D. M. MAFFT Multiple Sequence Alignment Software Version  
1529 7: Improvements in Performance and Usability. *Mol. Biol. Evol.* **30**, 772–780 (2013).  
1530 50. Matranga, C. B. *et al.* Enhanced methods for unbiased deep sequencing of Lassa  
1531 and Ebola RNA viruses from clinical and biological samples. *Genome Biol.* **15**, 519  
1532 (2014).

1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573




1574 **Extended Data Figures**



1575  
 1576 **Extended Data Figure 1. Detection of 21 respiratory viruses by mCARMEN and**  
 1577 **CARMEN v1. a,** Detailed schematic of loading and running 192.24 IFC in mCARMEN  
 1578 workflow. (Step 1) Up to 196 pre-amplified samples are added in the red microwells of

1579 the Fluidigm 192.24 Dynamic Array IFC. Up to 24 detection assay reactions containing  
1580 Cas13-crRNA complexes are added on the sides of the IFC shown in blue. Control line,  
1581 actuation, and pressure fluids are added according to manufacturer's guidelines. (Step  
1582 2) The IFC is loaded in a controller where the load and mix protocol is selected. In the  
1583 last minute of the protocol, the individual channels open to allow sample and detection  
1584 assay mixing to occur. (Step 3) Sequence specific Cas13-crRNA complexes recognize  
1585 and bind to RNA which unleashes the collateral cleavage activity of Cas13. Cas13  
1586 cleaves the quenched fluorescent reporter in solution. (Step 4) The IFC is loaded into  
1587 the Fluidigm Biomark after the controller protocol finishes. The Biomark, incubating at  
1588 37°C, takes images every 5 minutes for up to 3 hours to monitor fluorescence from the  
1589 detection reactions. **b**, Synthetic DNA fragments from each of the 21 human respiratory  
1590 viruses were serially diluted from  $10^3$ - $10^1$  copies/ $\mu$ L and added to Q5 amplification  
1591 master mix containing primer pool 1 or 2. After amplification, separate sample and  
1592 detection assay reactions were prepared for fluorescence-based readout using  
1593 CARMEN v1. CARMEN v1 values are shown as raw fluorescence (red), FAM signal at  
1594 3 hours. All samples were background subtracted from NTC-det negative control. **c**,  
1595 Time series curves of mCARMEN (blue) from Fig. 1b and CARMEN v1 (red) from **b** at  
1596 0, 60, and 180 minutes.


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




1597  
 1598 **Extended Data Figure 2. Enhanced sensitivity with polyU fluorescent reporter on**  
 1599 **patient specimens. a**, 6 SARS-CoV-2 positive and 4 SARS-CoV-2 negative NP swabs  
 1600 from Figure 1e. mCARMEN values are shown as normalized fluorescence (blue) and  
 1601 CARMEN v1 values are shown as raw fluorescence (red) while signal using the polyU  
 1602 reporter is shown directly above signal using RNase Alert (Thermo). **b**, Fluorescence  
 1603 over time for SARS-CoV-2 positive patient specimens, MGH-006. Top, mCARMEN  
 1604 fluorescence values for MGH-006 and NTC with blue line representing signal from the  
 1605 polyU reporter and black representing signal from RNase Alert at 0, 60, 120, and 180  
 1606 minutes. Bottom, CARMEN v1 fluorescence values, red line representing signal from  
 1607 polyU reporter and black representing signal from RNase Alert at 0, 60, and 180  
 1608 minutes. **c&d**, CARMEN v1 signal shown as raw fluorescence at 3 hr post-reaction  
 1609 initiation. 58 patient specimens were extracted using the KingFisher Flex MagMAX  
 1610 mirVana kit then amplified in 2 steps with 2 separate primer pools. **c**, Amplification from  
 1611 primer pool 1 **d**, amplification from primer pool 2. All specimens were background  
 1612 subtracted using NTC-amp as a negative control. Asterisks (\*) represent specimens

1613 with known infections by unbiased NGS, more than 10 reads mapped to the viral  
1614 genome.


1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637




1638  
 1639 **Extended Data Figure 3. Single-step amplification troubleshooting of synthetic**  
 1640 **material and patient specimens. a**, Fluorescence for SARS-CoV-2, FLUBV, and  
 1641 HMPV comparing four different single-step amplification kits Qiagen One-Step RT-PCR,  
 1642 TaqPath, QuantaBio, and Promega. **b**, Single-step amplification by Qiagen One-Step  
 1643 RT-PCR kit (top, blue) compared to two-step amplification by SSIV then Q5 (bottom,  
 1644 green) on 21 SARS-CoV-2 positive and 8 SARS-CoV-2 negative patient specimens.  
 1645 Prior RT-qPCR results shown as expected infection positive (+) or negative (-). All  
 1646 specimens were background subtracted using NTC-amp as a negative control. Asterisk  
 1647 (\*) represent differences between one-step and two-step amplification results.



1648  
 1649 **Extended Data Figure 4. mCARMEN RVP Software for automated results and hit**  
 1650 **calling. a**, RVP Analysis Software workflow. (Step 1) Once the software has been  
 1651 successfully launched, four sections must be filled in: Experiment name, Output  
 1652 directory, Raw data file, and Assignment sheet. The raw data file comes from the  
 1653 Biomark instrument after mCARMEN run is complete. The assignment sheet must be  
 1654 filled out prior to software analysis. (Step 2) Press start to run the RVP Software  
 1655 analysis. (Step 3) The analysis can take several minutes to run, but once complete the  
 1656 user can navigate to the specified Output directory to view the six output files. **b**,  
 1657 Example of a condensed heatmap from a successful mCARMEN RVP experiment  
 1658 ([Experiment Name\_heatmap\_t12.png). **c**, Snapshot of the key file that captures all the  
 1659 RVP results individually broken down by patient specimen ID and respiratory virus  
 1660 (Experiment Name\_HitQuantification.csv). The file lists the Specimen IDs accompanied  
 1661 by a positive, negative, or invalid determination, as defined in Clinical Evaluation of  
 1662 "Clinical Evaluation of RVP at MGH - Controls & Software Analysis." The CARMEN  
 1663 RVP Software is available at: <https://github.com/broadinstitute/carmen-rvp>.  
 1664



1665  
 1666 **Extended Data Figure 5. crRNA performance during RVP pre-clinical LOD**  
 1667 **evaluation.** **a**, Fluorescence for 12 replicate testing of SARS-CoV-2 viral seed stock at  
 1668 5,000, 2,500, 1,000, and 500 copies/mL spiked into negative patient specimens. All  
 1669 samples were background subtracted using NTC-amp as a negative control. Plus sign  
 1670 (+) represent negative sample call by mCARMEN results. **b&e**, Area under the receiver  
 1671 operating characteristic (AUROC) curve for crRNA detection. Blue bar represents the  
 1672 maximal AUROC time point at 60 minutes post-reaction initiation **c&f**, Evaluation of  
 1673 sensitivity and specificity of crRNA detection to establish hit calling threshold. Black line:  
 1674 sensitivity/true positive rate; gray line: specificity/true negative rate; red line: hit calling  
 1675 threshold. **d&g**, Confusion matrix of expected vs predicted detection. **b-d**, SARS-CoV-2  
 1676 crRNA detection only. **e-g**, all nine respiratory viruses on RVP.  
 1677




1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696

**Extended Data Figure 6. SARS-CoV-2 clinical specimen testing in an academic setting at the Broad.** **a**, Average normalized fluorescence for SARS-CoV-2 across 8-14 patient specimens within Ct ranges of 15-20, 20-22, 22-25, 25-30, and 30-34. Purple lines: known SARS-CoV-2 positive specimens; black line: known SARS-CoV-2 negative specimens; error bars: one standard deviation from the mean fluorescence. **b**, SARS-CoV-2 N1 RT-qPCR inconclusive specimens from Fig. 2c. Scatter plot of mean Ct of one or two technical replicates compared to mCARMEN scaled normalized fluorescence. **c**, Scatter plot of RNase P scaled normalized fluorescence from Fig. 1b compared to RNase P Ct values obtained from concurrent RT-qPCR testing of 533 patient specimens. Green: positive RNase P signal detected by both RVP and RT-qPCR; gray: inconclusive RT-qPCR result indicating one or two of the three technical replicates were undetermined; black: undetermined RT-qPCR result indicating all three technical replicates were negative for SARS-CoV-2. **d**, RNase P RT-qPCR inconclusive specimens from **c**. Scatter plot of mean Ct of one or two technical replicates compared to mCARMEN scaled normalized fluorescence. Green: positive detection by both RVP and RT-qPCR; purple: RVP positive; gray: RT-qPCR positive; black: negative by both RVP and RT-qPCR. Dashed horizontal lines: threshold for RVP positivity. Dashed vertical line: Ct value of 37 (FDA positivity cutoff).



1697



1698

1699

1700

1701

1702

1703

1704

1705

1706

1707

1708

1709

1710

1711

**Extended Data Figure 7. mCARMEN RVP sensitivity evaluation, LOD and co-**

**infections, at MGH. a**, Fluorescent values at the LOD of all 9 viruses on RVP as established by spiking viral seed stock, isolated RNA extracted from clinical specimens, or synthetic RNA into confirmed negative patient specimen for 20 replicates. NTC, no template control; Viral scaled normalized fluorescence values, circles; RNase P values, squares; NTC-noMg values, "X". **b**, Scaled normalized fluorescence values at 1 hr are shown for SARS-CoV-2 and RNase P, as well as another RVP virus. SARS-CoV-2 viral seed stock was spiked into pooled negative specimen at 2,000 copies/mL (2x the LOD established in Fig. 3b). Additionally, viral seed stock, isolated RNA extracted from clinical specimens, or synthetic RNA was additionally spiked at 10<sup>7</sup>-10<sup>3</sup> copies/mL. Error bars, one standard deviation from the median fluorescence. Blue: RVP virus at varying concentrations; light purple: SARS-CoV-2; black: RNase P from negative patient

1711 specimen. **c**, Concordance between RVP and Biofire RP 2.01/2.1 for 6 patient  
1712 specimens with co-infections visualized as a split heatmap. Purple: RVP and BioFire  
1713 2.0/2.1 positive; blue: RVP virus-positive; green: Biofire RP2.0/2.1 virus-positive; white:  
1714 virus-negative.

1715

1716

1717

1718

1719

1720


1721

1722


1723

1724

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



1725  
 1726 **Extended Data Figure 8. mCARMEN RVP specificity testing at MGH on *in silico***  
 1727 **designed synthetic targets and patient specimens. a,** Fluorescence at 1 hr post-  
 1728 reaction initiation on *in silico* designed synthetic targets spiked into pool negative patient  
 1729 specimen at  $10^6$  copies/ $\mu$ L for specificity evaluation. Plus sign (+) represent expected  
 1730 cross-reactive signal. Dashed vertical line for visual aid. **b,** Fluorescence at 1 hr for 166  
 1731 patient specimens with known infection status from Fig. 3d-f. Dashed vertical line for  
 1732 visual aid. **c,** Patient specimen summary from **b** comparing mCARMEN RVP and  
 1733 comparator assay results (Cepheid and BioFire 2.0/2.1). Asterisk (\*) represents co-  
 1734 infections that were confirmed by BioFire 2.0/2.1.



1735  
1736

1737 **Extended Data Figure 9. Agreement of mCARMEN patient and contrived samples**  
 1738 **tested in CLIA-certified laboratory at MGH. a,** Workflow of patient specimens  
 1739 evaluation. Patient specimens were originally tested by either Cepheid and BioFire  
 1740 RP2.0/2.1. We tested these specimens by both mCARMEN RVP and BioFire RP2.0/2.1  
 1741 then a subset of these specimens were subjected to unbiased NGS. **b,** Concordance  
 1742 between RVP and either Cepheid or BioFire RP2.0/2.1 for 166 patient specimens.  
 1743 Positive and negative percent agreements are shown in parenthesis. **c,** Concordance  
 1744 between RVP and NGS for 30 out of the 166 patient specimens. **d,** Concordance of

1745 contrived samples to RVP. Contrived samples were prepared by spiking viral seed  
1746 stock, genomic RNA, or synthetic RNA into negative patient specimen.

1747

1748

1749

1750

1751

1752

1753

1754

1755

1756

1757

1758

1759

1760

1761

1762

1763

1764

1765

1766

1767

1768

1769

1770

1771

1772


1773

1774

1775

1776


1777



1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787

**Extended Data Figure 10. Evaluation of crRNA pairs detecting SARS-CoV-2 spike gene mutations on synthetic targets.** 26 mutations across the SARS-CoV-2 spike gene were selected based on uniqueness within a variant lineage or due to phenotypic effects on viral fitness. *In vitro* transcribed synthetic RNA targets at  $10^{13}$  copies/mL were used as input. Top, positive values, represents signal on the derived sequence (mutation/ancestral) and bottom, negative values, represents signal on the ancestral sequence (ancestral/mutation). Bars represent log<sub>2</sub> maximum crRNA normalized fluorescence ratio at any 5 minute time point from 0-180 minutes after reaction initiation.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795

**Extended Data Figure 11. Mutation detection for Alpha, Beta, Gamma, and Delta SARS-CoV-2 variant lineages.** Kinetics curves of 4-7 SNPs that make up the four different variant lineage seed stocks being evaluated. Data shown as normalized fluorescence every five minutes for 3-4 concentrations of viral seed stock. WA, Alpha, Beta, Gamma:  $10^4$ - $10^2$  copies/ $\mu$ L, and Delta:  $10^3$ - $10^1$  copies/ $\mu$ L. Purple: variant lineage; Blue: ancestral seed stock; colored from high-to-low concentration. Shaded regions represent 95% confidence intervals around the median fluorescence values and lines

1796 are the median.

1797

1798


1799

1800

1801




It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



1802 **Extended Data Figure 12. crRNA performance in Variant Identification Panel (VIP).**  
 1803 **a**, Evaluation of sensitivity and specificity of crRNA pair detection to establish mutation  
 1804 calling threshold. All values based on viral seed stock testing. Black line: sensitivity/true  
 1805 positive rate; gray line: specificity/true negative rate; red line: mutation calling threshold.  
 1806 **b**, Summary of sensitivity and specificity results from **a**. Black: sensitivity; gray:  
 1807


1808 specificity.  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842

**Extended Data Figure 13. General variant identification analysis pipeline workflow and special cases.** **a**, Variant identification analysis pipeline method for making variant calls based on fluorescence signals from VIP assay. **b**, Alpha, Beta, Gamma, and Delta viral seed stocks were evaluated using VIP. Kinetic curve data shown as the  $\log_2$  of the maximum crRNA fluorescence ratio of mutation/ancestral at five min intervals for the first 60 min post-reaction initiation. Black: ancestral seed stock WA; purple: Alpha; blue: Beta; teal: Gamma; green: Delta. X lines represent the expected SNP based on NGS. O lines represent the unexpected SNP based on NGS. Dashed line represents threshold for variant calling based on Extended Data Fig. 12. **c**, Left, expected signal for the mutations that make up 5 SARS-CoV-2 variant lineages based on results from viral seed stock testing. Right, mutation calls from the variant identification analysis pipeline for three SARS-CoV-2 positive patient specimens where the analysis pipeline returns either a not identified result or an incorrectly identified variant result. Plus sign (+) represents signal that is either unexpected or expected for the given variant lineage based on NGS results.



1843  
1844 **Extended Data Figure 14. Sample quantification with combined Cas12 and Cas13**  
1845 **detection on mCARMEN RVP. a**, Kinetic curves of SARS-CoV-2 detection by both  
1846 Cas13 (blue) and Cas12 (orange) for 5 or 7 concentrations, respectively, up to 120 min.  
1847 Dashed lines represent the time at which signal reaches 50% (IC<sub>50</sub> infection point) for  
1848 each concentration of target. **b**, Standard curves for SARS-CoV-2 and FLUAV based on  
1849 RT-qPCR Ct values. Data related to Fig. 5c, now showing a standard 10-fold dilution  
1850 series.

1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865

Category	Cost (USD)	Notes
Fixed cost per chip	568.7	Includes reagents for Fluidigm and chip itself
Marginal cost per sample	9.27	Includes extraction, PCR reagents, and detection sample reagents
Marginal cost per virus tested	1.1	Includes CRISPR-Cas13a protein and assay reagents

1866 **Supplementary Table 1. Cost calculation breakdown concerning mCARMEN.**

1867

1868

1869 **Supplementary Table 2. Oligonucleotides related to this work.**

1870

1871

1872 **Supplementary Table 3. Patient specimens related to this work.**

1873

1874

Target	SARS-CoV-2							
copies/mL	10,000,000	1,000,000	100,000	10,000	1,000	100	10	1
Positive/total	5/5	5/5	5/5	5/5	3/5	0/5	0/5	0/5

Target	HCoV-HKU1							
copies/mL	10,000,000	1,000,000	100,000	10,000	1,000	100	10	1
Positive/total	5/5	5/5	5/5	4/5	2/5	0/5	0/5	0/5

Target	HCoV-NL63							
copies/mL	10,000,000	1,000,000	100,000	10,000	1,000	100	10	1
Positive/total	5/5	5/5	5/5	5/5	5/5	3/5	0/5	0/5

Target	HCoV-OC43							
copies/mL	10,000,000	1,000,000	100,000	10,000	1,000	100	10	1
Positive/total	5/5	5/5	5/5	4/5	2/5	2/5	0/5	0/5

Target	FLUAV							
copies/mL	10,000,000	1,000,000	100,000	10,000	1,000	100	10	1
Positive/total	5/5	5/5	5/5	3/5	2/5	0/5	0/5	0/5

Target	FLUBV							
copies/mL	10,000,000	1,000,000	100,000	10,000	1,000	100	10	1
Positive/total	5/5	5/5	5/5	5/5	5/5	1/5	0/5	0/5

Target	HPIV-3							
copies/mL	10,000,000	1,000,000	100,000	10,000	1,000	100	10	1

<b>Positive/total</b>	5/5	5/5	5/5	5/5	5/5	1/5	0/5	0/5
-----------------------	-----	-----	-----	-----	-----	-----	-----	-----

<b>Target</b>	<b>HRSV</b>							
<b>copies/mL</b>	10,000,000	1,000,000	100,000	10,000	1,000	100	10	1
<b>Positive/total</b>	5/5	5/5	5/5	5/5	3/5	0/5	1/5	0/5

<b>Target</b>	<b>HMPV</b>							
<b>copies/mL</b>	10,000,000	1,000,000	100,000	10,000	1,000	100	10	1
<b>Positive/total</b>	5/5	5/5	5/5	4/5	1/5	0/5	0/5	0/5

1875 **Supplementary Table 4. Preliminary limit of detection (LOD) results using**  
 1876 **synthetic targets from 1-10,000,000 copies/mL.** A range finding study for LOD for  
 1877 each target was conducted using synthetic materials spiked into pooled negative patient  
 1878 specimens stored in Universal Transport Medium (UTM). The range finding study was  
 1879 conducted with a dilution series ranging from 1 - 10,000,000 copies/mL. The estimated  
 1880 LOD range was determined for each viral target between the lowest dilution detected  
 1881 and the highest undetected concentration for the confirmatory experiments.  
 1882  
 1883

<b>Species/group</b>	<b>Taxonomic_ID</b>	<b>Total # of Sequences Evaluated</b>	<b>Homology (Forward Primer, Reverse Primer, crRNA)</b>	<b>Mismatch (Forward Primer, Reverse Primer, crRNA)</b>
SARS-CoV-2	2697049	>5000	100%, 99.8%, 99.8%	0, 0, 0
HCoV-HKU1	290028	40	100%, 99.5%, 100%	0, 0, 0
HCoV-NL63	277944	63	99.2%, 100%, 98.8%	0, 0, 0
HCoV-OC43	31631	143	100%, 100%, 100%	0, 0, 0
FLUAV	11320	1000 <sup>^</sup>	92.4%, 93.9%, 99.1%	2, 1, 0
FLUBV	11520	2601	99.4%, 96.4%, 91.9%	0, 1, 2
HMPV	162145	137	95.2%, 95.7%, 95.1%	1, 1, 1
HRSV	12814	423	99%, 96%, 97.3%*, 95.3%	0, 1, 1*, 1
HPIV-3	No TaxID for human PIV-3	321	97.9%, 99.3%, 97.5%	0, 0, 1

1884 <sup>^</sup>compressed based on serotype homology to reduce number of aligned sequences  
 1885 \*two reverse primers

1886 **Supplementary Table 5. *In silico* inclusivity evaluation of CARMEN-RVP.** Inclusivity  
 1887 was evaluated by performing an *in silico* analysis using all publicly available sequences  
 1888 of all targets on the panel. Inclusivity was tested by performing an *in silico* analysis  
 1889 using all publicly available sequences of all targets on the panel. Complete genomes for  
 1890 all viruses were downloaded from NCBI on April 2<sup>nd</sup> 2021 and aligned using MAFFT, a  
 1891 multiple sequence alignment program that stands for “Multiple Alignment using Fast  
 1892 Fourier Transform.” MAFFT utilizes several different alignment algorithms. For viral  
 1893 species with less than 1000 sequences, the FFT-NS-ix1000 algorithm was used to  
 1894 create the MAFFT alignment. For viral species with >1000 sequences, the FFT-NS-1  
 1895 algorithm was used to create the MAFFT alignment. The primer and crRNA sequences

1896 were then mapped to the aligned viral sequences using a consensus alignment to  
 1897 determine the percent identity (homology) and the number of mismatches. The average  
 1898 homology and mismatches were taken across the total number of sequences evaluated.  
 1899 Please note that mismatches below for crRNA sequences do not take wobble base  
 1900 pairing (G-U pairing) into account. Additionally the SARS-CoV-2 crRNA and primer  
 1901 sequences were compared by NCBI BLAST+ against the nr/nt databases (updated  
 1902 03/31/2021, N=68965867 sequences analyzed) and the Betacoronavirus database  
 1903 (updated 04/01/2021, N=140760). The search parameters were adjusted to blastn-short  
 1904 for short input sequences. The match and mismatch scores are 1 and -3, respectively.  
 1905 The penalty to create and extend a gap in an alignment is 5 and 2, respectively. Blast  
 1906 results confirmed only perfect matches to SARS-CoV-2.  
 1907  
 1908

Homology Sequences	Panel Sequences (Forward primer, reverse primer, crRNA)								
	Percent homology								
	SARS-CoV-2	HCoV-HKU1	HCoV-NL63	HCoV-OC43	FLUAV	FLUBV	HMPV	HRSV	HPIV-3
SARS-CoV-2	<b>100%</b>	63.30%	60.80%	61.80%	60%	64.40%	66.70%	54.60%	66.90%
HCoV-229E	65.40%	62.60%	72.10%	68.50%					
HCoV-HKU1	65.00%	<b>99.80%</b>	63.50%	74.50%					
HCoV-NL63	60.40%	62.90%	<b>99.30%</b>	68.90%					
HCoV-OC43	56%	72.90%	66.50%	<b>100%</b>					
HCoV-MERS	58.90%	59.80%	63.20%	63.10%					
SARS-CoV-1	62.90%	61.00%	53.90%	67.50%					
FLUAV	60.40%				<b>95.80%</b>	70.80%			
FLUBV	67.50%				77%	<b>95.90%</b>			
FLUCV	57.50%				69.50%	63.90%			
HMPV	48.80%						<b>95.30%</b>	71.90%	63%
HRSV	67.50%						59.10%	<b>96.90%</b>	56%
HPIV-3	68.30%						67.10%	61.50%	<b>98.20%</b>
HPIV-1	64.70%						63.20%	59.20%	68.90%
HPIV-2	63.40%						64.50%	64.70%	65%
HPIV-4	63.90%						55.80%	49%	60%
HRV	43.70%						46.30%	47.60%	43.80%
Ad71	22.90%								
EV-D68	60.90%								

1909 **Supplementary Table 6. *In silico* Cross-reactivity (analytical specificity) evaluation**  
 1910 **of CARMEN-RVP.** Complete genomes for all viruses were downloaded from NCBI on  
 1911 April 2nd 2021 and aligned using MAFFT. For viral species with less than 1000

1912 sequences, FFT-NS-ix1000 was used. For viral species with >1000 sequences, FFT-  
 1913 NS-1 was used for the MAFFT alignment. The primer and crRNA sequences were then  
 1914 mapped to the aligned viral sequences using a consensus alignment to determine  
 1915 percent identity (homology). The average homology was taken across the panel  
 1916 sequences and the total number of sequences evaluated. Bolded text represents on-  
 1917 target primers/crRNA to the intended viral sequences. Not all sequence combinations  
 1918 were evaluated since whole genome homology between many viruses is significantly  
 1919 less than 80%. None of the primer or crRNA sequences has >80% homology to other,  
 1920 unintended viral or bacterial sequences, making the panel highly specific to the  
 1921 particular viruses of interest. More specifically, no *in silico* cross-reactivity >80%  
 1922 homology between any primers and crRNA sequences on the CARMEN-RVP assay is  
 1923 observed for the following common respiratory flora and other viral pathogens: SARS-  
 1924 CoV-1, HCoV-MERS, Adenovirus, Enterovirus, Rhinovirus, *Chlamydia pneumoniae*,  
 1925 *Haemophilus influenzae*, *Legionella pneumophila*, *Mycobacterium tuberculosis*,  
 1926 *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Bordetella pertussis*,  
 1927 *Mycoplasma pneumoniae*, *Pneumocystis jirovecii*, *Candida albicans*, *Pseudomonas*  
 1928 *aeruginosa*, *Staphylococcus epidermis*, *Streptococcus salivarius*.

1929  
 1930

Virus Name	Cat#	Description	Vendor	NGS Amino Acid Substitutions
SARS-CoV-2	VR-1986HK	Viral seed stock	ATCC	N/A
HPIV-3	VR-93	Viral seed stock	ATCC	N/A
OC43	VR-1558	Viral seed stock	BEI Resources	N/A
HRSV	VR-1540	Viral seed stock	ATCC	N/A
FLUA(H3N2)	NR-43756	Genomic RNA	BEI Resources	N/A
FLUBV	VR-1804	Genomic RNA	BEI Resources	N/A
HMPV	NR-49122	Genomic RNA	ATCC	N/A
SARS-CoV-2 Alpha	N/A	Viral seed stock	CDC	H69-, V70-, Y144-, N501Y, A570D, D614G, P681H, T716I, A771X, S982A, D1118H
SARS-CoV-2 Beta	N/A	Viral seed stock	CDC	L18F, D80A, D215G, T240~, L241-, L242-, A243~, K417N, E484K, N501Y, D614G, A701V, A771X
SARS-CoV-2 Gamma	N/A	Viral seed stock	CDC	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, A771X, T1027I, R1039X, V1176F
SARS-CoV-2 Delta	N/A	Viral seed stock	CDC	T19R, G142D, E156-, F157-, R158G, L452R, T478K, D614G, P681R, D950N
SARS-CoV-2 Epsilon	N/A	Viral seed stock	CDC	S13I, P26S, W152C, L452R, D614G, A771X, R1039X

1931 **Supplementary Table 7. Viral seed stock and genomic RNA information related to**  
 1932 **this work.**